Prestige Consumer Healthcare (PBH) 10-Q 7 Nov 13 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Entity Information [Line Items]	'	'
Entity Registrant Name	'Prestige Brands Holdings, Inc.	'
Entity Central Index Key	'0001295947	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Large Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	51,714,249

Consolidated_Statements_of_Inc

Consolidated Statements of Income and Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues	'	'	'	'
Net sales	$167,004	$161,323	$309,105	$307,243
Other revenues	1,438	532	2,308	1,609
Total revenues	168,442	161,855	311,413	308,852
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	73,723	71,310	133,211	134,703
Gross profit	94,719	90,545	178,202	174,149
Operating Expenses	'	'	'	'
Advertising and promotion	26,044	23,508	45,184	43,833
General and administrative	11,619	12,585	23,253	28,736
Depreciation and amortization	3,294	3,296	6,562	6,591
Total operating expenses	40,957	39,389	74,999	79,160
Operating income	53,762	51,156	103,203	94,989
Other (income) expense	'	'	'	'
Interest income	-25	-3	-28	-5
Interest expense	16,464	19,663	32,372	39,513
Total other expense	16,439	19,660	32,344	39,508
Income before income taxes	37,323	31,496	70,859	55,481
Provision for income taxes	4,531	12,252	17,375	21,582
Net income	32,792	19,244	53,484	33,899
Earnings per share:	'	'	'	'
Basic (in USD per share)	$0.64	$0.38	$1.04	$0.67
Net income (in USD per share)	$0.63	$0.38	$1.03	$0.66
Weighted average shares outstanding:	'	'	'	'
Basic (in shares)	51,463	50,364	51,343	50,353
Diluted (in shares)	52,219	51,225	52,130	51,166
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	1,122	66	1,123	24
Total other comprehensive income	1,122	66	1,123	24
Comprehensive income	$33,914	$19,310	$54,607	$33,923

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$26,833	$15,670
Accounts receivable, net	80,534	73,053
Inventories	61,935	60,201
Deferred income tax assets	6,427	6,349
Prepaid expenses and other current assets	6,929	8,900
Total current assets	182,658	164,173
Property and equipment, net	11,256	9,896
Goodwill	191,058	167,546
Intangible assets, net	1,399,860	1,373,240
Other long-term assets	23,244	24,944
Total Assets	1,808,076	1,739,799
Current liabilities	'	'
Accounts payable	51,857	51,376
Accrued interest payable	13,951	13,894
Other accrued liabilities	23,301	31,398
Total current liabilities	89,109	96,668
Long-term debt	'	'
Principal amount	985,000	978,000
Less unamortized discount	-6,302	-7,100
Long-term debt, net of unamortized discount	978,698	970,900
Deferred income tax liabilities	198,721	194,288
Other long-term liabilities	296	0
Total Liabilities	1,266,824	1,261,856
Commitments and Contingencies — Note 17	'	'
Stockholders' Equity	'	'
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Preferred share rights	283	283
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 51,905 shares at September 30, 2013 and 51,311 shares at March 31, 2013	520	513
Additional paid-in capital	410,664	401,691
Treasury stock, at cost - 191 shares at September 30, 2013 and181 shares at March 31, 2013	-965	-687
Accumulated other comprehensive income (loss), net of tax	1,019	-104
Retained earnings	129,731	76,247
Total Stockholders' Equity	541,252	477,943
Total Liabilities and Stockholders' Equity	$1,808,076	$1,739,799

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Stockholders' Equity:	'	'
Preferred stock, par value (in USD per share)	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$0.01	$0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	51,905,000	51,311,000
Treasury stock, shares	191,000	181,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating Activities	'	'
Net income	$53,484	$33,899
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	6,562	6,591
Deferred income taxes	4,355	12,391
Amortization of deferred financing costs	1,975	2,060
Stock-based compensation costs	2,487	1,973
Amortization of debt discount	798	812
Lease termination costs	0	975
(Gain) loss on sale or disposal of equipment	-3	51
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-5,712	-24,530
Inventories	821	-2,904
Prepaid expenses and other current assets	2,619	5,556
Accounts payable	-1,125	15,150
Accrued liabilities	-10,663	8,350
Net cash provided by operating activities	55,598	60,374
Investing Activities	'	'
Purchases of property and equipment	-2,319	-5,266
Proceeds from the sale of property and equipment	3	15
Acquisition of brands from GSK purchase price adjustments	0	-226
Acquisition of Care Pharmaceuticals, less cash acquired	-55,215	0
Net cash used in investing activities	-57,531	-5,477
Financing Activities	'	'
Repayments of long-term debt	-7,500	-70,000
Repayments under revolving credit agreement	-35,500	-8,000
Borrowings under revolving credit agreement	50,000	33,000
Payment of deferred financing costs	-275	0
Proceeds from exercise of stock options	5,143	80
Excess tax benefits from share-based awards	1,350	0
Fair value of shares surrendered as payment of tax withholding	-278	0
Net cash provided by (used in) financing activities	12,940	-44,920
Effects of exchange rate changes on cash and cash equivalents	156	14
Increase in cash and cash equivalents	11,163	9,991
Cash and cash equivalents - beginning of period	15,670	19,015
Cash and cash equivalents - end of period	26,833	29,006
Interest paid	29,516	36,524
Income taxes paid	$8,468	$656

Business_and_Basis_of_Presenta

Business and Basis of Presentation	6 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Business and Basis of Presentation	'
	Business and Basis of Presentation
	Nature of Business
	Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, club, convenience, and dollar stores in the United States and Canada and in certain other international markets.  Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to the Consolidated Financial Statements.
	Basis of Presentation
	The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2014”) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three and six months ended September 30, 2013 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2014.  This financial information should be read in conjunction with our Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
	Cash and Cash Equivalents
	We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at September 30, 2013 are uninsured.
	Accounts Receivable
	We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
	Inventories
	Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.
	Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
	Goodwill
	The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.
	Intangible Assets
	Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year.   If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized
	Deferred Financing Costs
	We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method, over the term of the related debt.
	Revenue Recognition
	Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.
	As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results.
	Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
	Cost of Sales
	Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.  Shipping, warehousing and handling costs were $9.1 million and $15.7 million for the three and six months ended September 30, 2013, respectively, and $7.3 million and $15.5 million for the three and six months ended September 30, 2012, respectively.
	Advertising and Promotion Costs
	Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
	Stock-based Compensation
	We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period an employee or director is required to provide service in exchange for the award, generally referred to as the requisite service period.
	Income Taxes
	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.
	We are subject to taxation in the United States and various state and foreign jurisdictions.
	We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
	Earnings Per Share
	Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.
	Recently Issued Accounting Standards
	In July 2013, the FASB issued Accounting Standards Updated ("ASU") 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which requires that an unrecognized tax benefit, or portion of an unrecognized tax benefit, be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. If an applicable deferred tax asset is not available to use or the tax law of the applicable jurisdiction does not require the entity to use and the company does not intend to use the applicable deferred tax asset, the unrecognized tax benefit should be presented as a liability in the financial statements and should not be combined with an unrelated deferred tax asset. ASU 2013-11 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date; however retrospective application is permitted. The adoption of ASU 2013-11 is not expected to have a material impact on our Consolidated Financial Statements.
	In March 2013, the FASB issued ASU 2013-05, Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, relating to the release of cumulative translation adjustments into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on our Consolidated Financial Statements.
	In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires that for those items that are reclassified out of accumulated other comprehensive income and into net income in their entirety, the effect of the reclassification on each affected net income line item be disclosed. For accumulated other comprehensive income reclassification items that are not reclassified in their entirety into net income, a cross reference must be made to other required disclosures. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. ASU 2013-02 did not have a material impact on our Consolidated Financial Statements. See Note 13, Accumulated Other Comprehensive Income (Loss) for required disclosure.
	In December 2011, the FASB issued ASU 2011-11, Disclosures about Offsetting Assets and Liabilities, regarding disclosures about offsetting assets and liabilities. The new disclosure requirements mandate that entities disclose both gross and net information about instruments and transactions eligible for offset in the statement of financial position, as well as instruments and transactions subject to an agreement similar to a master netting arrangement. In addition, the standard requires disclosure of collateral received and posted in connection with master netting agreements or similar arrangements. An entity will be required to disclose the following information for assets and liabilities within the scope of the new standard: (i) the gross amounts of those recognized assets and those recognized liabilities; (ii) the amounts offset to determine the net amounts presented in the statement of financial position; (iii) the net amounts presented in the statement of financial position; (iv) the amounts subject to an enforceable master netting arrangement or similar agreement not otherwise included in (ii); and (v) the net amount after deducting the amounts in (iv) from the amounts in (iii). The standard affects all entities with balances presented on a net basis in the financial statements, derivative assets and derivative liabilities, repurchase agreements, and financial assets and financial liabilities executed under a master netting or similar arrangement. This guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. This new guidance did not have a material impact on our Consolidated Financial Statements.
	Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Acquisitions

Acquisitions	6 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions
	Acquisition of Care Pharmaceuticals Pty Ltd.
	On July 1, 2013, we completed the acquisition of Care Pharmaceuticals Pty Ltd. (“Care”), which was funded through a combination of our existing senior secured credit facility and cash on hand.
	The Care brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care also carries a line of brands for children including Little Allergies, Little Eyes, and Little Cough. The brands acquired are complementary to our existing OTC Healthcare portfolio.
	This acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.
	We prepared a preliminary analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.
	(In thousands)	July 1, 2013
	Cash acquired	$	1,546
	Accounts receivable, net	1,658
	Inventories	2,465
	Prepaids and other current assets	647
	Property, plant and equipment, net	163
	Goodwill	23,122
	Intangible assets	31,502
	Total assets acquired	61,103
	Accounts payable	1,537
	Accrued expenses	2,505
	Other long term liabilities	300
	Total liabilities assumed	4,342
	Net assets acquired	$	56,761
	Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at September 30, 2013 was 14.9 years.
	We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.
	The pro-forma effect of this acquisition on revenues and earnings was not material.
	Acquisition of certain OTC Brands from GlaxoSmithKline
	On December 20, 2011, we entered into two separate agreements with GlaxoSmithKline ("GSK") to acquire a total of 17 North American OTC healthcare brands (the "GSK Brands") for $660.0 million in cash (the "GSK Agreement").
	On January 31, 2012, we completed, subject to a post-closing inventory and apportionment adjustment, as defined in the GSK Agreement, the acquisition of 15 North American OTC healthcare brands previously owned by GSK and its affiliates (the “GSK Brands I”) for $615.0 million in cash, including the related contracts, trademarks and inventory. The GSK Brands I include, among other brands, BC, Goody's and Ecotrin brands of pain relievers; Beano, Gaviscon, Phazyme, Tagamet and Fiber Choice gastrointestinal brands; and the Sominex sleep aid brand.
	On March 30, 2012, we completed, subject to a post-closing inventory and apportionment adjustment, as defined in the GSK Agreement, the acquisition of the Debrox and Gly-Oxide brands (the “GSK Brands II”) in the United States for $45.0 million in cash, including the related contracts, trademarks and inventory.
	Both the GSK Brands I and GSK Brands II are complementary to our existing OTC healthcare portfolio.
	These acquisitions were accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.
	The purchase price of the GSK Brands I and GSK Brands II was funded by cash provided by the issuance of long-term debt and additional bank borrowings, which are discussed further in Note 10. In April 2012, we received the post-closing inventory and apportionment adjustments, which required us to pay an additional $2.8 million to GSK, and in May 2012 we received a revised post-closing inventory and apportionment adjustment, which required us to pay an additional $0.2 million, for a total of $3.0 million, to GSK.
	Concurrent with the closing of the GSK Brands I transaction, we entered into a Transitional Services Agreement with GSK (the “TSA”), whereby GSK provided us with various services, including marketing, operations, finance and other services, from the GSK Brands I acquisition date primarily through June 30, 2012, with additional finance support through August 31, 2012. As part of the TSA, GSK, among other things, shipped products, invoiced customers, collected from customers and paid certain vendors on our behalf. Our initial costs under the TSA were approximately $2.5 million per month for the length of the agreement and were reduced during the service period as we removed certain services and processes to us. We incurred $6.8 million in TSA costs for the three months ended June 30, 2012. Pursuant to the TSA, we received on a monthly basis the amount owed to us for revenues and expenses, net of GSK's TSA fees and inventory that GSK purchased on our behalf.
	The allocation of the purchase price to assets acquired under the GSK Agreement is based on a valuation we performed to determine the fair value of such assets as of the acquisition date. The following table summarizes our allocation of the $663.0 million purchase price to the assets we acquired on the GSK Brands acquisition dates:
	(In thousands)		GSK Brands I (January 31, 2012)		GSK Brands II (March 30, 2012)		Total
	Inventory		$	14,820	$	250	$	15,070
	Prepaid expenses		3,575		—		3,575
	Trade names		542,892		81,257		624,149
	Goodwill		17,401		2,831		20,232
	Total purchase price		$	578,688	$	84,338	$	663,026
	We recorded goodwill based on the amount by which the purchase price exceeded the fair value of assets acquired. The amount of goodwill deductible for tax purposes is $20.2 million.
	The fair value of the trade names is comprised of $556.9 million of non-amortizable intangible assets and $67.2 million of amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 19.3 years. The weighted average remaining life for amortizable intangible assets at September 30, 2013 was 17.5 years.

Divestitures

Divestitures	6 Months Ended
	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Divestitures	'
	Divestitures
	Sale of the Phazyme Brand
	On October 31, 2012, we divested the Phazyme gas treatment brand, which was a non-core OTC brand that we acquired from GSK in January 2012. We received $21.7 million from the divestitures on October 31, 2012 and the remaining $0.6 million on January 4, 2013. The proceeds were used to repay debt. No significant gain or loss was recorded as a result of the sale.
	Concurrent with the completion of the sale of the Phazyme brand, we entered into a Transitional Services Agreement with the buyer (the “Phazyme TSA”), whereby we agreed to provide the buyer with various services, including: marketing, operations, finance and other services, from the date of the acquisition primarily through January 31, 2013, with an option for additional support for the Canadian portion of that business through October 31, 2013, at the buyer's discretion. All Phazyme United States TSA services ended, as agreed, on January 31, 2013. The buyer elected to extend the Canadian portion of the TSA services and terminate the support on October 31, 2013.
	The following table presents the assets sold at October 31, 2012 related to the Phazyme brand:
	(In thousands)	October 31,
		2012
	Components of assets sold:
	Inventory	$	220
	Prepaid expenses	100
	Trade names	15,604
	Goodwill	6,382

Accounts_Receivable

Accounts Receivable	6 Months Ended
	Sep. 30, 2013
Receivables [Abstract]	'
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable consist of the following:
	(In thousands)	September 30,			March 31,
		2013			2013
	Components of Accounts Receivable
	Trade accounts receivable	$	87,966		$	79,746
	Other receivables	731			615
		88,697			80,361
	Less allowances for discounts, returns and uncollectible accounts	(8,163		)	(7,308		)
	Accounts receivable, net	$	80,534		$	73,053

Inventories

Inventories	6 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following:
	(In thousands)	September 30,		March 31,
		2013		2013
	Components of Inventories
	Packaging and raw materials	$	1,034	$	1,875
	Finished goods	60,901		58,326
	Inventories	$	61,935	$	60,201
	Inventories are carried at the lower of cost or market, which includes a reduction in inventory values of $2.2 million and $1.3 million at September 30, 2013 and March 31, 2013, respectively, related to obsolete and slow-moving inventory.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	Property and equipment consist of the following:
	(In thousands)	September 30,			March 31,
		2013			2013
	Components of Property and Equipment
	Machinery	$	1,672		$	1,580
	Computer equipment	8,788			6,559
	Furniture and fixtures	1,808			1,510
	Leasehold improvements	4,732			4,713
		17,000			14,362
	Accumulated depreciation	(5,744		)	(4,466		)
	Property and equipment, net	$	11,256		$	9,896
	We recorded depreciation expense of $0.5 million and $0.4 million for the three months ended September 30, 2013 and September 30, 2012, respectively, and $1.1 million and $0.6 million for the six months ended September 30, 2013 and September 30, 2012, respectively.

Goodwill

Goodwill	6 Months Ended
	Sep. 30, 2013
Goodwill [Abstract]	'
Goodwill	'
	Goodwill
	A reconciliation of the activity affecting goodwill by operating segment is as follows:
	(In thousands)	OTC		Household		Consolidated
		Healthcare		Cleaning
	Balance — March 31, 2013	$	160,157	$	7,389	$	167,546
	Additions	23,122		—		23,122
	Effects of foreign currency exchange rates	390		—		390
	Balance — September 30, 2013	$	183,669	$	7,389	$	191,058
	As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care. In connection with this acquisition, we recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired.
	Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.
	On an annual basis, during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of the values assigned to goodwill and tests for impairment.
	At March 31, 2013, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2013. As of September 30, 2013, no indicators of impairment existed and no impairment charge was recorded.
	The discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2013, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

Intangible_Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2013
Intangible Assets [Abstract]	'
Intangible Assets	'
	Intangible Assets
	A reconciliation of the activity affecting intangible assets is as follows:
	(In thousands)	Indefinite			Finite Lived		Non Compete			Totals
		Lived			Trademarks		Agreement
		Trademarks
	Gross Carrying Amounts
	Balance — March 31, 2013	$	1,243,718		$	203,066	$	158		$	1,446,942
	Additions	29,845			1,657		—			31,502
	Reductions	—			—		(158		)	(158		)
	Effects of foreign currency exchange rates	512			29		—			541
	Balance — September 30, 2013	$	1,274,075		$	204,752	$	—		$	1,478,827
	Accumulated Amortization
	Balance — March 31, 2013	$	—		$	73,544	$	158		$	73,702
	Additions	—			5,423		—			5,423
	Reductions	—			—		(158		)	(158		)
	Balance — September 30, 2013	$	—		$	78,967	$	—		$	78,967
	Intangible assets, net - September 30, 2013	$	1,274,075		$	125,785	$	—		$	1,399,860
	As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care. In connection with this acquisition, we allocated $31.5 million to intangible assets based on our preliminary analysis.
	Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount.  Additionally, at each reporting period an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life.  Intangible assets with finite lives are amortized over their respective estimated useful lives and must also be tested for impairment annually or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.
	On an annual basis, during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.
	In a manner similar to goodwill, we completed our annual test for impairment of our indefinite-lived intangible assets during the three months ended March 31, 2013.  We did not record an impairment charge, as facts and circumstances indicated that the fair values of the intangible assets for our brands exceeded their carrying values. Additionally, for the indefinite-lived intangible assets, an evaluation of the facts and circumstances as of September 30, 2013 continues to support an indefinite useful life for these assets. Therefore, no impairment charge was recorded for the six months ended September 30, 2013.
	The weighted average remaining life for finite-lived intangible assets at September 30, 2013 was approximately 14.2 years and the amortization expense for the three and six months ended September 30, 2013 was $2.7 million and $5.4 million. At September 30, 2013, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:
	(In thousands)
	Year Ending March 31,		Amount
	2014 (Remaining six months ending March 31, 2014)		$	4,820
	2015		8,951
	2016		8,951
	2017		8,951
	2018		8,951
	Thereafter		85,161
			$	125,785

Other_Accrued_Liabilities

Other Accrued Liabilities	6 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Other Accrued Liabilities	'
	Other Accrued Liabilities
	Other accrued liabilities consist of the following:
	(In thousands)	September 30,		March 31,
		2013		2013
	Accrued marketing costs	$	14,223	$	17,187
	Accrued compensation costs	3,781		8,847
	Accrued broker commissions	2,137		1,028
	Income taxes payable	350		493
	Accrued professional fees	1,146		1,846
	Deferred rent	1,311		1,268
	Accrued lease termination costs	341		729
	Other accrued liabilities	12		—
		$	23,301	$	31,398

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-Term Debt
	On March 24, 2010, Prestige Brands, Inc. (the "Borrower") issued $150.0 million of senior unsecured notes, with an interest rate of 8.25% and a maturity date of April 1, 2018 (the "2010 Senior Notes"). On November 1, 2010, the Borrower issued an additional $100.0 million of the 2010 Senior Notes. The Borrower may earlier redeem some or all of the 2010 Senior Notes at redemption prices set forth in the indenture governing the 2010 Senior Notes. The 2010 Senior Notes issued in March and November 2010 were issued at an aggregate face value of $150.0 million and $100.0 million, respectively, with a discount to the initial purchasers of $2.2 million and a premium of $0.3 million, respectively, and net proceeds to the Company of $147.8 million and $100.3 million, respectively, yielding an 8.5% effective interest rate for the 2010 Senior Notes on a combined basis. The 2010 Senior Notes are unconditionally guaranteed by Prestige Brands Holdings, Inc. and its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.
	On January 31, 2012, the Borrower issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.
	On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In September 2012, we utilized a portion of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $25.0 million to $75.0 million, and in June 2013, we further increased the amount of our borrowing capacity under the 2012 ABL Revolver by $20.0 million to $95.0 million and also reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Company of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.
	On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Amendment") to the 2012 Term Loan. The Amendment provides for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans. The interest rate on the Term B-1 Loans is based, at the Borrower's option, on a LIBOR rate, plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, plus a margin. The new Term B-1 Loans will mature on the same date as the Term B Loans original maturity date. In addition, the Amendment provides the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement.  In connection with the refinancing, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.
	The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs, provided that LIBOR shall not be lower than 1.00%. For the six months ended September 30, 2013, the average interest rate on the 2012 Term Loan was 3.8%.
	Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make a payment until the maturity date of January 31, 2019.
	Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments in an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the six months ended September 30, 2013, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.9%.
	We used the net proceeds from the 2012 Senior Notes offering, together with borrowings under the 2012 Term Loan, to finance the acquisition of the GSK Brands, to repay the 2010 Credit Facility, to pay fees and expenses incurred in connection with these transactions and for general corporate purposes. The acquisition of the GSK Brands is discussed in Note 2.
	At September 30, 2013, we had $23.2 million of unamortized debt issuance costs and $6.3 million of unamortized debt discount. The total of which is comprised of $3.0 million related to the 2010 Senior Notes, $10.7 million related to the 2012 Senior Notes, $14.4 million related to the 2012 Term Loan, and $1.4 million related to the 2012 ABL Revolver.
	The 2010 Senior Notes are secured on a pari passu basis with the 2012 Term Loan and are guaranteed on a senior secured basis. The 2012 Senior Notes are senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis. The 2010 Senior Notes are effectively junior in right of payment to all existing and future secured obligations of the Company, equal in right of payment with all existing and future senior unsecured indebtedness of the Company, and senior in right of payment to all future subordinated debt of the Company. The 2012 Senior Notes are effectively subordinated to secured obligations of the Company, including the 2012 Term Loan and the 2012 ABL Revolver and the 2010 Senior Notes, equal in right of payment to all existing and future unsecured obligations of the Company, and senior in right of payment to all existing and future subordinated obligations of the Company.
	At any time prior to April 1, 2014, we may redeem the 2010 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a “make-whole premium” calculated as set forth in the indenture governing the 2010 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. We may redeem the 2010 Senior Notes in whole or in part at any time on or after the 12-month period beginning April 1, 2014 at a redemption price of 104.125% of the principal amount thereof, at a redemption price of 102.063% of the principal amount thereof if the redemption occurs during the 12-month period beginning on April 1, 2015, and at a redemption price of 100% of the principal amount thereof if the redemption occurs on and after April 1, 2016, in each case, plus accrued and unpaid interest, if any, to the redemption date. In addition, prior to April 1, 2013, with the net cash proceeds from certain equity offerings, we could have redeemed up to 35% in aggregate principal amount of the 2010 Senior Notes at a redemption price of 108.250% of the principal amount of the 2010 Senior Notes to be redeemed, plus accrued and unpaid interest, if any, to the redemption date.
	At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we may redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.
	The indentures governing the 2010 Senior Notes and 2012 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indenture governing the 2012 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement and the indenture governing the 2012 Senior Notes. At September 30, 2013, we were in compliance with the covenants under our long-term indebtedness.
	During the six months ended September 30, 2013, we borrowed a net amount of $14.5 million against the 2012 ABL Revolver.
	Long-term debt consists of the following, as of the dates indicated:
	(In thousands, except percentages)	September 30,			March 31,
		2013			2013
	2012 Senior Notes bearing interest at 8.125%, with interest only payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	$	250,000		$	250,000
	2012 Term Loan bearing interest at the Company's option at either a base rate plus applicable margin with a floor of 2.00% or LIBOR with a floor of 1.00%, due on January 31, 2019.	437,500			445,000
	2012 ABL Revolver bearing interest at the Company's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	47,500			33,000
	2010 Senior Notes bearing interest at 8.25%, with interest only payable on April 1 and October 1 of each year. The 2010 Senior Notes mature on April 1, 2018.	250,000			250,000
		985,000			978,000
	Less: unamortized discount	(6,302		)	(7,100		)
	Long-term debt, net of unamortized discount	$	978,698		$	970,900
	Aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the 2010 Senior Notes and the 2012 Senior Notes are as follows:
	(In thousands)
	Year Ending March 31,	Amount
	2014 (remaining six months ending March 31, 2014)	$	—
	2015	—
	2016	—
	2017	47,500
	2018	—
	Thereafter	937,500
		$	985,000

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.
	The Fair Value Measurements and Disclosures topic of the FASB ASC requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:
	Level 1 - Quoted market prices for identical instruments in active markets;
	Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and
	Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.
	The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2012 Term Loan, the 2012 Senior Notes, the 2010 Senior Notes and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At September 30, 2013 and March 31, 2013, we did not have any assets or liabilities measured in Level 1 or 3. During any of the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3.
	At September 30, 2013 and March 31, 2013, the carrying value of our 2012 Senior Notes was $250.0 million. The market value of our 2012 Senior Notes was $276.9 million and $281.9 million at September 30, 2013 and March 31, 2013, respectively.
	At September 30, 2013 and March 31, 2013, the carrying value of the 2012 Term Loan was $437.5 million and $445.0 million, respectively. The market value of the 2012 Term Loan was $439.1 million and $451.1 million at September 30, 2013 and March 31, 2013, respectively.
	At September 30, 2013 and March 31, 2013, the carrying value of our 2010 Senior Notes was $250.0 million.  The market value of our 2010 Senior Notes was $266.3 million and $271.9 million at September 30, 2013 and March 31, 2013, respectively.
	At September 30, 2013, the carrying value and market value of the 2012 ABL Revolver was $47.5 million. At March 31, 2013, the carrying value and market value of the 2012 ABL Revolver was $33.0 million.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders' Equity
	The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share.  The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.
	Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders.  The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends.  No dividends have been declared or paid on the Company's common stock through September 30, 2013.
	Pursuant to the provisions of various employee restricted stock awards, we repurchased zero shares and 10,726 shares of restricted common stock from our employees during the three and six months ended September 30, 2013, respectively. During the three and six months ended September 30, 2012, we did not repurchase any shares of restricted common stock from our employees pursuant to the provisions of the various employee restricted stock awards. The repurchases during the six months ended September 30, 2013 were at an average price of $25.96. All of the repurchased shares have been recorded as treasury stock.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Accumulated Other Comprehensive Income (Loss)	'
	Accumulated Other Comprehensive Income (Loss)
	The table below presents accumulated other comprehensive income (loss) (“AOCI”), which is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. As discussed in Note 1 above, ASU 2013-02 did not have a significant impact on our financial statements.
	AOCI consisted of the following at September 30, 2013 and March 31, 2013:
		September 30,		March 31,
	(In thousands)	2013		2013
	Components of Accumulated Other Comprehensive Income (Loss)
	Cumulative translation adjustment	$	1,019	$	(104	)
	Total accumulated other comprehensive income (loss)	$	1,019	$	(104	)

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:
		Three Months Ended September 30,				Six Months Ended September 30,
	(In thousands, except per share data)	2013		2012		2013		2012
	Numerator
	Net income	$	32,792	$	19,244	$	53,484	$	33,899
	Denominator
	Denominator for basic earnings per share — weighted average shares outstanding	51,463		50,364		51,343		50,353
	Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	756		861		787		813
	Denominator for diluted earnings per share	52,219		51,225		52,130		51,166
	Earnings per Common Share:
	Basic net earnings per share	$	0.64	$	0.38	$	1.04	$	0.67
	Diluted net earnings per share	$	0.63	$	0.38	$	1.03	$	0.66
	For the three months ended September 30, 2013 and 2012, there were 0.2 million and 0.3 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the six months ended September 30, 2013 and 2012, there were 0.2 million and 0.4 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-based Compensation	'
	Share-Based Compensation
	In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for the grant of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards.  Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.
	During the three months and six months ended September 30, 2013, pre-tax share-based compensation costs charged against income were $1.3 million and $2.5 million, respectively, and the related income tax benefit recognized was $0.3 million and $0.7 million, respectively.  During the three and six months ended September 30, 2012, pre-tax share-based compensation costs charged against income were $1.1 million and $2.0 million, respectively, and the related income tax benefit recognized was $0.3 million and $0.6 million, respectively.
	Restricted Shares and Restricted Stock Units
	Restricted shares and restricted stock units granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals by the Company, including revenue and earnings before income taxes, depreciation and amortization targets.  The restricted share and restricted stock unit awards provide for accelerated vesting if there is a change of control, as defined in the Plan.  On May 14, 2013, the Compensation Committee of our Board of Directors granted 113,637 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 55,637 restricted stock units vest in their entirety on the three-year anniversary of the date of grant, and 58,000 restricted stock units vest 33.3% per year over three years. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. On July 29, 2013, the Compensation Committee of the Board of Directors granted 7,004 restricted stock units to the independent members of the Board of Directors under the Plan.
	The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. The fair value of the restricted stock units is determined using the closing price of our common stock on the day of grant. The weighted-average grant-date fair value of restricted stock units granted during the six months ended September 30, 2013 and 2012 was $30.19 and $13.59, respectively.
	A summary of the Company's restricted shares and restricted stock units granted under the Plan is presented below:
					Weighted-
			Shares		Average
			(in thousands)		Grant-Date
	Restricted Shares and Restricted Stock Units				Fair Value
	Six months ended September 30, 2012:
	Outstanding at March 31, 2012		363.4		$	9.92
	Granted		128.9		13.59
	Vested and issued		(27.0	)	7.16
	Forfeited		(4.3	)	11.06
	Outstanding at September 30, 2012		461		11.1
	Vested at September 30, 2012		70.4		8.52
	Six months ended September 30, 2013:
	Outstanding at March 31, 2013		421.3		$	11.01
	Granted		120.6		30.19
	Vested and issued		(54.7	)	8.11
	Forfeited		(3.6	)	13.24
	Outstanding at September 30, 2013		483.6		16.11
	Vested at September 30, 2013		83.1		9.63
	Options
	The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted.  Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years.  The option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below.  Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies.  We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors.  Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation.  The expected terms of the options granted are derived from management's estimates and consideration of information derived from the public filings of companies similar to us and represent the period of time that options granted are expected to be outstanding.  The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option.  On May 14, 2013, the Compensation Committee of our Board of Directors granted stock options to acquire 227,672 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $29.94 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.
	The weighted-average grant-date fair value of the options granted during the six months ended September 30, 2013 and 2012 was $13.94 and $6.03, respectively.
		Six Months Ended September 30,
		2013			2012
	Expected volatility	48		%	44		%
	Expected dividends	$	—		$	—
	Expected term in years	6			6.5
	Risk-free rate	1.3		%	1.2		%
	A summary of option activity under the Plan is as follows:
					Weighted-			Weighted-	Aggregate
					Average			Average	Intrinsic
			Shares		Exercise			Remaining	Value
			(in thousands)		Price			Contractual	(in thousands)
	Options							Term
	Six months ended September 30, 2012:
	Outstanding at March 31, 2012		1,745.40		$	8.44
	Granted		444.9		13.36
	Exercised		(6.8	)	11.84
	Forfeited or expired		(11.7	)	10.99
	Outstanding at September 30, 2012		2,171.80		9.43			7.6	$	16,602
	Exercisable at September 30, 2012		1,027.70		8.39			6.9	7,132
	Six months ended September 30, 2013:
	Outstanding at March 31, 2013		1,386.40		$	10.43
	Granted		227.7		29.94
	Exercised		(539.4	)	9.54
	Forfeited or expired		(8.0	)	13.24
	Outstanding at September 30, 2013		1,066.70		15.02			6.5	$	16,110
	Exercisable at September 30, 2013		225.5		11.42			7.7	4,216
	The aggregate intrinsic value of options exercised in the six months ended September 30, 2013 was $12.5 million. At September 30, 2013, there was no significant intrinsic value for options granted during the six months ended September 30, 2013, as the exercise price of these options was only slightly less than the closing price of our common stock as of September 30, 2013.
	At September 30, 2013, there were $6.1 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest.  We expect to recognize such costs over a weighted-average period of 1.0 year.  The total fair value of options and restricted shares vested during the six months ended September 30, 2013 and 2012 was $3.2 million and $2.0 million, respectively.  For the six months ended September 30, 2013 and 2012, cash received from the exercise of stock options was $5.1 million and less than $0.1 million, respectively, and we realized $1.7 million and less than $0.1 million, respectively, in tax benefits for the tax deductions resulting from these option exercises. At September 30, 2013, there were 1.6 million shares available for issuance under the Plan.

Income_Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur.  The effective tax rate used in the calculation of income taxes was 12.1% and 38.9% for the three months ended September 30, 2013 and September 30, 2012, respectively. The effective tax rate used in the calculation of income taxes was 24.5% and 38.9% for the six months ended September 30, 2013 and September 30, 2012, respectively. The decrease in the effective tax rate for the three and six months ended September 30, 2013 was primarily due to a one-time benefit of $9.1 million to adjust our current and deferred tax balances for lower state income taxes. This benefit was primarily related to a recent law change in the state where we have our major distribution center to tax earnings attributed to in-state revenues only.
	At September 30, 2013, a wholly-owned subsidiary had a net operating loss carryforward of approximately $1.1 million, which may be used to offset future taxable income of the consolidated group and which begins to expire in 2020.  The net operating loss carryforward is subject to an annual limitation as to usage of approximately $0.2 million pursuant to Internal Revenue Code Section 382.
	We experienced no change in our uncertain tax liability during the six months ended September 30, 2013. Therefore, the balance in our uncertain tax liability was $1.0 million at September 30, 2013 and March 31, 2013. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense.  We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	We are involved from time to time in routine legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition or results from operations.
	Lease Commitments
	We have operating leases for office facilities and equipment in New York and Wyoming, which expire at various dates through 2018. Due to the acquisition of the GSK Brands, we required additional office space and entered into a 5.5 year lease for a new office facility in New York, which began in the third quarter of fiscal 2013. In May 2012, we also entered into a three year office lease in Rogers, Arkansas. These amounts have been included in the schedule below.
	The following summarizes future minimum lease payments for our operating leases as of September 30, 2013:
	(In thousands)
	Year Ending March 31,	Facilities		Equipment		Total
	2014 (Remaining six months ending March 31, 2014)	$	1,024	$	82	$	1,106
	2015	1,049		136		1,185
	2016	994		135		1,129
	2017	1,023		68		1,091
	2018	1,044		—		1,044
	Thereafter	—		—		—
		$	5,134	$	421	$	5,555
	Rent expense for each of the three months ended September 30, 2013 and 2012 was $0.5 million and $0.3 million, respectively, while rent expense for each of the six months ended September 30, 2013 and 2012 was $0.8 million and $0.6 million, respectively.
	Purchase Commitments
	Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products.  Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.
	(In thousands)
	Year Ending March 31,	Amount
	2014 (Remaining six months ending March 31, 2014)	$	564
	2015	1,105
	2016	1,074
	2017	1,044
	2018	1,013
	Thereafter	1,542
		$	6,342

Concentrations_of_Risk

Concentrations of Risk	6 Months Ended
	Sep. 30, 2013
Risks and Uncertainties [Abstract]	'
Concentrations of Risk	'
	Concentrations of Risk
	Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products.  We sell our products to mass merchandisers, food and drug stores, and dollar and club stores.  During the three and six months ended September 30, 2013, approximately 41.8% and 43.0%, respectively, of our total revenues were derived from our five top selling brands.  During the three and six months ended September 30, 2012, approximately 40.3% and 41.3%, respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 19.2% and 20.4%, respectively, of our gross revenues for the three and six months ended September 30, 2013, and approximately 16.3% and 18.1%, respectively, of our gross revenues for the three and six months ended September 30, 2012. At September 30, 2013, approximately 19.7% of accounts receivable were owed by the same customer.
	We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri.  A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost.  We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center.  As a result, any such disruption could have a material adverse effect on our business, sales and profitability.
	At September 30, 2013, we had relationships with 50 third-party manufacturers.  Of those, we had long-term contracts with 22 manufacturers that produced items that accounted for approximately 77.9% of gross sales for the six months ended September 30, 2013. At September 30, 2012, we had relationships with 61 third-party manufacturers.  Of those, we had long-term contracts with 28 manufacturers that produced items that accounted for approximately 84.9% of gross sales for the six months ended September 30, 2012. The fact that we do not have long-term contracts with certain manufacturers means they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition and results from operations.

Business_Segments

Business Segments	6 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Business Segments	'
	Business Segments
	Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current operating and reportable segments consist of (i) OTC Healthcare and (ii) Household Cleaning. There were no inter-segment sales or transfers during any of the periods presented.  We evaluate the performance of our operating segments and allocate resources to them based primarily on contribution margin.
	The tables below summarize information about our operating and reportable segments.
		Three Months Ended September 30, 2013										Six Months Ended September 30, 2013
	(In thousands)	OTC			Household			Consolidated				OTC		Household		Consolidated
		Healthcare			Cleaning							Healthcare		Cleaning
	Net sales	$	142,454		$	24,550		$	167,004			$	265,222	$	43,883	$	309,105
	Other revenues	155			1,283			1,438				312		1,996		2,308
	Total revenues	142,609			25,833			168,442				265,534		45,879		311,413
	Cost of sales	55,325			18,398			73,723				100,336		32,875		133,211
	Gross profit	87,284			7,435			94,719				165,198		13,004		178,202
	Advertising and promotion	25,313			731			26,044				43,545		1,639		45,184
	Contribution margin	$	61,971		$	6,704		68,675				$	121,653	$	11,365	133,018
	Other operating expenses							14,913								29,815
	Operating income							53,762								103,203
	Other expense							16,439								32,344
	Income before income taxes							37,323								70,859
	Provision for income taxes							4,531								17,375
	Net income							$	32,792							$	53,484
		Three Months Ended September 30, 2012										Six Months Ended September 30, 2012
	(In thousands)	OTC			Household			Consolidated				OTC		Household		Consolidated
		Healthcare			Cleaning							Healthcare		Cleaning
	Net sales	$	137,771		$	23,552		$	161,323			$	263,775	$	43,468	$	307,243
	Other revenues	164			368			532				345		1,264		1,609
	Total revenues	137,935			23,920			161,855				264,120		44,732		308,852
	Cost of sales	53,469			17,841			71,310				100,868		33,835		134,703
	Gross profit	84,466			6,079			90,545				163,252		10,897		174,149
	Advertising and promotion	22,046			1,462			23,508				39,899		3,934		43,833
	Contribution margin	$	62,420		$	4,617		67,037				$	123,353	$	6,963	130,316
	Other operating expenses							15,881								35,327
	Operating income							51,156								94,989
	Other expense							19,660								39,508
	Income before income taxes							31,496								55,481
	Provision for income taxes							12,252								21,582
	Net income							$	19,244							$	33,899
	The table below summarizes information about our revenues from similar product groups.
		Three Months Ended September 30,					Six Months Ended September 30,
	(In thousands)	2013		2012			2013			2012
	Analgesics	$	30,508	$	26,106		$	58,731		$	53,781
	Cough & Cold	33,636		32,969			55,218			56,773
	Gastrointestinal	22,814		25,329			44,651			49,533
	Eye & Ear Care	21,417		21,700			44,119			43,407
	Dermatologicals	16,494		15,600			30,426			30,082
	Oral Care	13,278		12,549			24,437			23,079
	Other OTC	4,462		3,682			7,952			7,465
	Total OTC Healthcare Segment	142,609		137,935			265,534			264,120
	Household Cleaning Segment	25,833		23,920			45,879			44,732
	Consolidated Total Revenues	$	168,442	$	161,855		$	311,413		$	308,852
	During the three and six months ended September 30, 2013, approximately 86.9% and 87.8%, respectively, of our sales were made to customers in the United States, while during the three and six months ended September 30, 2012, approximately 89.3% and 90.3%, respectively, of our sales were made to customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three and six months ended September 30, 2013, sales to Canada accounted for approximately 7.2% and 7.6%, respectively, of our total revenues, while during the three and six months ended September 30, 2012 approximately 8.1% and 7.3%, respectively, of our total revenue was attributable to sales to Canada.
	At September 30, 2013, substantially all of our long-term assets were located in the United States and have been allocated to the operating segments as follows:
	(In thousands)	OTC			Household			Consolidated
		Healthcare			Cleaning
	Goodwill	$	183,669		$	7,389		$	191,058
	Intangible assets
	Indefinite-lived	1,154,255			119,820			1,274,075
	Finite-lived	98,746			27,039			125,785
		1,253,001			146,859			1,399,860
		$	1,436,670		$	154,248		$	1,590,918

Condensed_Consolidating_Financ

Condensed Consolidating Financial Statements	6 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Condensed Consolidating Financial Statements	'
	Condensed Consolidating Financial Statements
	As described in Note 10, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, have fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2012 Senior Notes and the 2010 Senior Notes, including, without limitation, the obligation to pay principal and interest with respect to the 2012 Senior Notes and the 2010 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2012 Senior Notes and the 2010 Senior Notes are as follows: Prestige Personal Care Holdings, Inc., Prestige Personal Care, Inc., Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2012 Senior Notes and the 2010 Senior Notes. Although holders of the 2012 Senior Notes and the 2010 Senior Notes will be direct creditors of the guarantors of the 2012 Senior Notes and the 2010 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom and in the Netherlands (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2012 Senior Notes or the 2010 Senior Notes, and such subsidiaries will not be obligated with respect to the 2012 Senior Notes or the 2010 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2012 Senior Notes and the 2010 Senior Notes.
	Presented below are supplemental Condensed Consolidating Balance Sheets as of September 30, 2013 and March 31, 2013, Condensed Consolidating Income and Comprehensive Income Statements for the three and six months ended September 30, 2013 and 2012, and Condensed Consolidating Statements of Cash Flows for the six months ended September 30, 2013 and 2012. Such consolidating information includes separate columns for:
	a)  Prestige Brands Holdings, Inc., the parent,
	b)  Prestige Brands, Inc., the issuer,
	c)  Combined Subsidiary Guarantors,
	d)  Combined Non-Guarantor Subsidiaries, and
	e)  Elimination entries necessary to consolidate the Company and all of its subsidiaries.
	The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.
	Condensed Consolidating Statements of Income and Comprehensive Income
	Three Months Ended September 30, 2013
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	25,391		$	134,164		$	7,449		$	—		$	167,004
	Other revenues	—			67			1,431			668			(728		)	1,438
	Total revenues	—			25,458			135,595			8,117			(728		)	168,442
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			9,338			61,513			3,600			(728		)	73,723
	Gross profit	—			16,120			74,082			4,517			—			94,719
	Operating Expenses
	Advertising and promotion	—			3,748			20,899			1,397			—			26,044
	General and administrative	891			1,481			7,781			1,466			—			11,619
	Depreciation and amortization	517			143			2,589			45			—			3,294
	Total operating expenses	1,408			5,372			31,269			2,908			—			40,957
	Operating income (loss)	(1,408		)	10,748			42,813			1,609			—			53,762
	Other (income) expense
	Interest income	(12,778		)	(14,005		)	(710		)	(22		)	27,490			(25		)
	Interest expense	8,687			16,464			18,093			710			(27,490		)	16,464
	Equity in income of subsidiaries	(30,922		)	27,475			(1,189		)	—			4,636			—
	Total other (income) expense	(35,013		)	29,934			16,194			688			4,636			16,439
	Income before income taxes	33,605			(19,186		)	26,619			921			(4,636		)	37,323
	Provision (benefit) for income taxes	813			922			3,064			(268		)	—			4,531
	Net income (loss)	$	32,792		$	(20,108	)	$	23,555		$	1,189		$	(4,636	)	$	32,792
	Comprehensive income, net of tax:
	Currency translation adjustments	1,122			—			—			1,122			(1,122		)	1,122
	Total other comprehensive income (loss)	1,122			—			—			1,122			(1,122		)	1,122
	Comprehensive income (loss)	$	33,914		$	(20,108	)	$	23,555		$	2,311		$	(5,758	)	$	33,914
	Condensed Consolidating Statements of Income and Comprehensive Income
	Six Months Ended September 30, 2013
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	49,650		$	250,783		$	8,672		$	—		$	309,105
	Other revenues	—			135			2,294			1,102			(1,223		)	2,308
	Total revenues	—			49,785			253,077			9,774			(1,223		)	311,413
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			18,796			111,502			4,136			(1,223		)	133,211
	Gross profit	—			30,989			141,575			5,638			—			178,202
	Operating Expenses
	Advertising and promotion	—			7,188			36,392			1,604			—			45,184
	General and administrative	2,390			3,124			16,238			1,501			—			23,253
	Depreciation and amortization	1,034			285			5,184			59			—			6,562
	Total operating expenses	3,424			10,597			57,814			3,164			—			74,999
	Operating income (loss)	(3,424		)	20,392			83,761			2,474			—			103,203
	Other (income) expense
	Interest income	(24,991		)	(28,328		)	(710		)	(24		)	54,025			(28		)
	Interest expense	17,294			32,372			36,021			710			(54,025		)	32,372
	Equity in income of subsidiaries	(50,777		)	12,922			(1,868		)	—			39,723			—
Total other (income) expense	(58,474		)	16,966			33,443			686			39,723			32,344
Income before income taxes	55,050			3,426			50,318			1,788			(39,723		)	70,859
Provision (benefit) for income taxes	1,566			4,009			11,880			(80		)	—			17,375
Net income (loss)	$	53,484		$	(583	)	$	38,438		$	1,868		$	(39,723	)	$	53,484
Comprehensive income, net of tax:
Currency translation adjustments	1,123			—			—			1,123			(1,123		)	1,123
Total other comprehensive income (loss)	1,123			—			—			1,123			(1,123		)	1,123
Comprehensive income (loss)	$	54,607		$	(583	)	$	38,438		$	2,991		$	(40,846	)	$	54,607
Condensed Consolidating Statements of Income and Comprehensive Income
Three Months Ended September 30, 2012
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	26,727		$	133,277		$	1,319		$	—		$	161,323
Other revenues	—			74			524			519			(585		)	532
Total revenues	—			26,801			133,801			1,838			(585		)	161,855
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			10,175			61,175			545			(585		)	71,310
Gross profit	—			16,626			72,626			1,293			—			90,545
Operating Expenses
Advertising and promotion	—			2,777			20,410			321			—			23,508
General and administrative	895			1,707			9,977			6			—			12,585
Depreciation and amortization	137			139			3,004			16			—			3,296
Total operating expenses	1,032			4,623			33,391			343			—			39,389
Operating income (loss)	(1,032		)	12,003			39,235			950			—			51,156
Other (income) expense
Interest income	(12,242		)	(11,061		)	—			(54		)	23,354			(3		)
Interest expense	8,746			28,410			5,861			—			(23,354		)	19,663
Equity in income of subsidiaries	(17,738		)	(20,995		)	(780		)	—			39,513			—
Total other (income) expense	(21,234		)	(3,646		)	5,081			(54		)	39,513			19,660
Income before income taxes	20,202			15,649			34,154			1,004			(39,513		)	31,496
Provision (benefit) for income taxes	958			(2,080		)	12,983			391			—			12,252
Net income	$	19,244		$	17,729		$	21,171		$	613		$	(39,513	)	$	19,244
Comprehensive income, net of tax:
Currency translation adjustments	66			—			—			66			(66		)	66
Total other comprehensive income	66			—			—			66			(66		)	66
Comprehensive income	$	19,310		$	17,729		$	21,171		$	679		$	(39,579	)	$	19,310
Condensed Consolidating Statements of Income and Comprehensive Income
Six Months Ended September 30, 2012
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	49,949		$	254,934		$	2,360		$	—		$	307,243
Other revenues	—			141			1,586			994			(1,112		)	1,609
Total revenues	—			50,090			256,520			3,354			(1,112		)	308,852
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			18,616			116,210			989			(1,112		)	134,703
Gross profit	—			31,474			140,310			2,365			—			174,149
Operating Expenses
Advertising and promotion	—			5,884			37,330			619			—			43,833
General and administrative	2,724			3,436			22,067			509			—			28,736
Depreciation and amortization	269			280			6,009			33			—			6,591
Total operating expenses	2,993			9,600			65,406			1,161			—			79,160
Operating income (loss)	(2,993		)	21,874			74,904			1,204			—			94,989
Other (income) expense
Interest income	(24,370		)	(22,021		)	—			(101		)	46,487			(5		)
Interest expense	17,412			56,926			11,662			—			(46,487		)	39,513
Equity in income of subsidiaries	(31,476		)	(40,873		)	(913		)	—			73,262			—
Total other (income) expense	(38,434		)	(5,968		)	10,749			(101		)	73,262			39,508
Income before income taxes	35,441			27,842			64,155			1,305			(73,262		)	55,481
Provision (benefit) for income taxes	1,542			(5,069		)	24,601			508			—			21,582
Net income	$	33,899		$	32,911		$	39,554		$	797		$	(73,262	)	$	33,899
Comprehensive income, net of tax:
Currency translation adjustments	24			—			—			24			(24		)	24
Total other comprehensive income	24			—			—			24			(24		)	24
Comprehensive income	$	33,923		$	32,911		$	39,554		$	821		$	(73,286	)	$	33,923
Condensed Consolidating Balance Sheet
September 30, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Assets
Current assets
Cash and cash equivalents	$	23,668		$	—		$	—		$	3,165		$	—		$	26,833
Accounts receivable, net	133			12,879			63,667			3,855			—			80,534
Inventories	—			13,139			45,401			3,395			—			61,935
Deferred income tax assets	232			885			5,310			—			—			6,427
Prepaid expenses and other current assets	2,286			240			4,396			411			(404		)	6,929
Total current assets	26,319			27,143			118,774			10,826			(404		)	182,658
Property and equipment, net	10,791			20			182			263			—			11,256
Goodwill	—			66,007			101,539			23,512			—			191,058
Intangible assets, net	—			193,128			1,174,410			32,322			—			1,399,860
Other long-term assets	—			23,244			—			—			—			23,244
Intercompany receivable	654,016			1,918,831			496,358			9,102			(3,078,307		)	—
Investment in subsidiary	1,538,436			682,450			8,936			—			(2,229,822		)	—
Total Assets	$	2,229,562		$	2,910,823		$	1,900,199		$	76,025		$	(5,308,533	)	$	1,808,076
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,084		$	9,304		$	36,222		$	4,247		$	—		$	51,857
Accrued interest payable	—			13,951			—			—			—			13,951
Other accrued liabilities	6,476			1,804			13,096			2,329			(404		)	23,301
Total current liabilities	8,560			25,059			49,318			6,576			(404		)	89,109
Long-term debt
Principal amount	—			985,000			—			—			—			985,000
Less unamortized discount	—			(6,302		)	—			—			—			(6,302		)
Long-term debt, net of unamortized discount	—			978,698			—			—			—			978,698
Deferred income tax liabilities	—			54,679			143,970			72			—			198,721
Long term liabilities	—			—			—			296			—			296
Intercompany payable	1,679,749			435,445			928,333			34,780			(3,078,307		)	—
Total Liabilities	1,688,309			1,493,881			1,121,621			41,724			(3,078,711		)	1,266,824
Stockholders' Equity
Preferred share rights	283			—			—			—			—			283
Common stock	520			—			—			—			—			520
Additional paid-in capital	410,664			1,337,706			658,799			23,815			(2,020,320		)	410,664
Treasury stock, at cost - 191 shares	(965		)	—			—			—			—			(965		)
Accumulated other comprehensive income, net of tax	1,019			—			—			1,019			(1,019		)	1,019
Retained earnings (accumulated deficit)	129,731			79,236			119,780			9,467			(208,483		)	129,731
Total Stockholders' Equity	541,252			1,416,942			778,579			34,301			(2,229,822		)	541,252
Total Liabilities and Stockholders' Equity	$	2,229,561		$	2,910,823		$	1,900,200		$	76,025		$	(5,308,533	)	$	1,808,076
Condensed Consolidating Balance Sheet
March 31, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Assets
Current assets
Cash and cash equivalents	$	14,720		$	—		$	—		$	950		$	—		$	15,670
Accounts receivable, net	21			13,875			58,345			812			—			73,053
Inventories	—			11,164			48,474			563			—			60,201
Deferred income tax assets	218			855			5,276			—			—			6,349
Prepaid expenses and other current assets	4,942			93			3,609			256			—			8,900
Total current assets	19,901			25,987			115,704			2,581			—			164,173
Property and equipment, net	9,609			34			253			—			—			9,896
Goodwill	—			66,007			101,539			—			—			167,546
Intangible assets, net	—			193,396			1,179,524			320			—			1,373,240
Other long-term assets	—			24,944			—			—			—			24,944
Intercompany receivable	653,049			1,911,573			415,587			7,316			(2,987,525		)	—
Investment in subsidiary	1,429,775			638,611			7,067			—			(2,075,453		)	—
Total Assets	$	2,112,334		$	2,860,552		$	1,819,674		$	10,217		$	(5,062,978	)	$	1,739,799
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,601		$	10,600		$	37,695		$	480		$	—		$	51,376
Accrued interest payable	—			13,894			—			—			—			13,894
Other accrued liabilities	12,694			1,684			16,107			913			—			31,398
Total current liabilities	15,295			26,178			53,802			1,393			—			96,668
Long-term debt
Principal amount	—			978,000			—			—			—			978,000
Less unamortized discount	—			(7,100		)	—			—			—			(7,100		)
Long-term debt, net of unamortized discount	—			970,900			—			—			—			970,900
Deferred income tax liabilities	—			55,291			138,924			73			—			194,288
Intercompany payable	1,619,096			447,419			920,865			145			(2,987,525		)	—
Total Liabilities	1,634,391			1,499,788			1,113,591			1,611			(2,987,525		)	1,261,856
Stockholders' Equity
Preferred share rights	283			—			—			—			—			283
Common stock	513			—			—			—			—			513
Additional paid-in capital	401,691			1,280,945			624,742			1,111			(1,906,798		)	401,691
Treasury stock, at cost - 181 shares	(687		)	—			—			—			—			(687		)
Accumulated other comprehensive loss, net of tax	(104		)	—			—			(104		)	104			(104		)
Retained earnings (accumulated deficit)	76,247			79,819			81,341			7,599			(168,759		)	76,247
Total Stockholders' Equity	477,943			1,360,764			706,083			8,606			(2,075,453		)	477,943
Total Liabilities and Stockholders' Equity	$	2,112,334		$	2,860,552		$	1,819,674		$	10,217		$	(5,062,978	)	$	1,739,799
Condensed Consolidating Statement of Cash Flows
Six Months Ended September 30, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Operating Activities
Net income (loss)	$	53,484		$	(583	)	$	38,438		$	1,868		$	(39,723	)	$	53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Deferred income taxes	(14		)	(642		)	5,012			(1		)	—			4,355
Amortization of deferred financing costs	—			1,975			—			—			—			1,975
Stock-based compensation costs	2,487			—			—			—			—			2,487
Amortization of debt discount	—			798			—			—			—			798
Gain on sale of assets	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(50,777		)	12,922			(1,868		)	—			39,723			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(112		)	996			(5,322		)	(1,274		)	—			(5,712		)
Inventories	—			(1,975		)	3,073			(277		)	—			821
Prepaid expenses and other current assets	2,656			(147		)	(787		)	493			404			2,619
Accounts payable	(517		)	(1,296		)	(1,473		)	2,161			—			(1,125		)
Accrued liabilities	(6,218		)	177			(3,011		)	(1,207		)	(404		)	(10,663		)
Net cash provided by operating activities	2,023			12,510			39,243			1,822			—			55,598
Investing Activities
Purchases of property and equipment	(2,216		)	—			—			(103		)	—			(2,319		)
Proceeds from the sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash provided by (used in) investing activities	(2,216		)	(55,215		)	3			(103		)	—			(57,531		)
Financing Activities
Repayments of long-term debt	—			(7,500		)	—			—			—			(7,500		)
Repayments under revolving credit agreement	—			(35,500		)	—			—			—			(35,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(275		)	—			—			—			(275		)
Proceeds from exercise of stock options	5,143			—			—			—			—			5,143
Excess tax benefits from share-based awards	1,350			—			—			—			—			1,350
Shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	2,926			35,980			(39,246		)	340			—			—
Net cash provided by (used in) financing activities	9,141			42,705			(39,246		)	340			—			12,940
Effect of exchange rate changes on cash and cash equivalents	—			—			—			156			—			156
Increase in cash and cash equivalents	8,948			—			—			2,215			—			11,163
Cash - beginning of period	14,720			—			—			950			—			15,670
Cash - end of period	$	23,668		$	—		$	—		$	3,165		$	—		$	26,833
Condensed Consolidating Statement of Cash Flows
Six Months Ended September 30, 2012
(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	33,899		$	32,911		$	39,554		$	797		$	(73,262	)	$	33,899
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	269			280			6,009			33			—			6,591
Deferred income taxes	109			1,676			10,612			(6		)	—			12,391
Amortization of deferred financing costs	—			2,060			—			—			—			2,060
Stock-based compensation costs	1,973			—			—			—			—			1,973
Lease termination costs	975			—			—			—			—			975
Amortization of debt discount	—			812			—			—			—			812
Loss on disposal of equipment	30			—			21			—			—			51
Equity in income of subsidiaries	(31,476		)	(40,873		)	(913		)	—			73,262			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(117		)	(1,935		)	(21,910		)	(568		)	—			(24,530		)
Inventories	—			205			(3,319		)	210			—			(2,904		)
Prepaid expenses and other current assets	6,259			(48		)	(980		)	325			—			5,556
Accounts payable	(2,394		)	2,759			14,109			676			—			15,150
Accrued liabilities	(2,516		)	424			10,229			213			—			8,350
Net cash provided by (used in) operating activities	7,011			(1,729		)	53,412			1,680			—			60,374
Investing Activities
Purchases of property and equipment	(5,266		)	—			—			—			—			(5,266		)
Proceeds from sale of property and equipment	—			—			15			—			—			15
Acquisition of GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash provided by (used in) investing activities	(5,492		)	—			15			—			—			(5,477		)
Financing Activities
Repayment of long-term debt	—			(70,000		)	—			—			—			(70,000		)
Repayments under revolving credit agreement	—			(8,000		)	—			—			—			(8,000		)
Borrowings under revolving credit agreement	—			33,000			—			—			—			33,000
Proceeds from exercise of stock options	80			—			—			—			—			80
Intercompany activity, net	7,902			46,729			(53,427		)	(1,204		)	—			—
Net cash provided by (used in) financing activities	7,982			1,729			(53,427		)	(1,204		)	—			(44,920		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			14			—			14
Increase in cash and cash equivalents	9,501			—			—			490			—			9,991
Cash - beginning of period	18,221			—			—			794			—			19,015
Cash - end of period	$	27,722		$	—		$	—		$	1,284		$	—		$	29,006

Business_and_Basis_of_Presenta1

Business and Basis of Presentation (Policies)	6 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2014”) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three and six months ended September 30, 2013 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2014.  This financial information should be read in conjunction with our Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.
Accounts Receivable	'
	Accounts Receivable
	We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.
	Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Goodwill	'
	Goodwill
	The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.
Intangible Assets	'
	Intangible Assets
	Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year.   If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized
Deferred Financing Costs	'
	Deferred Financing Costs
	We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method, over the term of the related debt.
Revenue Recognition	'
	Revenue Recognition
	Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.
	As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results.
	Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
Cost of Sales	'
	Cost of Sales
	Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.
Advertising and Promotion Costs	'
	Advertising and Promotion Costs
	Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
Stock-based Compensation	'
	Stock-based Compensation
	We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period an employee or director is required to provide service in exchange for the award, generally referred to as the requisite service period.
Income Taxes	'
	Income Taxes
	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.
	We are subject to taxation in the United States and various state and foreign jurisdictions.
	We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
Earnings Per Share	'
	Earnings Per Share
	Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	In July 2013, the FASB issued Accounting Standards Updated ("ASU") 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which requires that an unrecognized tax benefit, or portion of an unrecognized tax benefit, be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. If an applicable deferred tax asset is not available to use or the tax law of the applicable jurisdiction does not require the entity to use and the company does not intend to use the applicable deferred tax asset, the unrecognized tax benefit should be presented as a liability in the financial statements and should not be combined with an unrelated deferred tax asset. ASU 2013-11 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date; however retrospective application is permitted. The adoption of ASU 2013-11 is not expected to have a material impact on our Consolidated Financial Statements.
	In March 2013, the FASB issued ASU 2013-05, Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, relating to the release of cumulative translation adjustments into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on our Consolidated Financial Statements.
	In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires that for those items that are reclassified out of accumulated other comprehensive income and into net income in their entirety, the effect of the reclassification on each affected net income line item be disclosed. For accumulated other comprehensive income reclassification items that are not reclassified in their entirety into net income, a cross reference must be made to other required disclosures. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. ASU 2013-02 did not have a material impact on our Consolidated Financial Statements. See Note 13, Accumulated Other Comprehensive Income (Loss) for required disclosure.
	In December 2011, the FASB issued ASU 2011-11, Disclosures about Offsetting Assets and Liabilities, regarding disclosures about offsetting assets and liabilities. The new disclosure requirements mandate that entities disclose both gross and net information about instruments and transactions eligible for offset in the statement of financial position, as well as instruments and transactions subject to an agreement similar to a master netting arrangement. In addition, the standard requires disclosure of collateral received and posted in connection with master netting agreements or similar arrangements. An entity will be required to disclose the following information for assets and liabilities within the scope of the new standard: (i) the gross amounts of those recognized assets and those recognized liabilities; (ii) the amounts offset to determine the net amounts presented in the statement of financial position; (iii) the net amounts presented in the statement of financial position; (iv) the amounts subject to an enforceable master netting arrangement or similar agreement not otherwise included in (ii); and (v) the net amount after deducting the amounts in (iv) from the amounts in (iii). The standard affects all entities with balances presented on a net basis in the financial statements, derivative assets and derivative liabilities, repurchase agreements, and financial assets and financial liabilities executed under a master netting or similar arrangement. This guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. This new guidance did not have a material impact on our Consolidated Financial Statements.
	Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Business_and_Basis_of_Presenta2

Business and Basis of Presentation (Tables)	6 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Property and Equipment	'
	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Acquisitions_Tables

Acquisitions (Tables)	6 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Preliminary Purchase Price Allocation	'
	The following table summarizes our allocation of the $663.0 million purchase price to the assets we acquired on the GSK Brands acquisition dates:
	(In thousands)		GSK Brands I (January 31, 2012)		GSK Brands II (March 30, 2012)		Total
	Inventory		$	14,820	$	250	$	15,070
	Prepaid expenses		3,575		—		3,575
	Trade names		542,892		81,257		624,149
	Goodwill		17,401		2,831		20,232
	Total purchase price		$	578,688	$	84,338	$	663,026
	The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.
	(In thousands)	July 1, 2013
	Cash acquired	$	1,546
	Accounts receivable, net	1,658
	Inventories	2,465
	Prepaids and other current assets	647
	Property, plant and equipment, net	163
	Goodwill	23,122
	Intangible assets	31,502
	Total assets acquired	61,103
	Accounts payable	1,537
	Accrued expenses	2,505
	Other long term liabilities	300
	Total liabilities assumed	4,342
	Net assets acquired	$	56,761

Divestitures_Tables

Divestitures (Tables)	6 Months Ended
	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Assets Sold and Associated Assets Held for Sale	'
	The following table presents the assets sold at October 31, 2012 related to the Phazyme brand:
	(In thousands)	October 31,
		2012
	Components of assets sold:
	Inventory	$	220
	Prepaid expenses	100
	Trade names	15,604
	Goodwill	6,382

Accounts_Receivable_Tables

Accounts Receivable (Tables)	6 Months Ended
	Sep. 30, 2013
Receivables [Abstract]	'
Accounts Receivable	'
	Accounts receivable consist of the following:
	(In thousands)	September 30,			March 31,
		2013			2013
	Components of Accounts Receivable
	Trade accounts receivable	$	87,966		$	79,746
	Other receivables	731			615
		88,697			80,361
	Less allowances for discounts, returns and uncollectible accounts	(8,163		)	(7,308		)
	Accounts receivable, net	$	80,534		$	73,053

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories consist of the following:
	(In thousands)	September 30,		March 31,
		2013		2013
	Components of Inventories
	Packaging and raw materials	$	1,034	$	1,875
	Finished goods	60,901		58,326
	Inventories	$	61,935	$	60,201

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and equipment consist of the following:
	(In thousands)	September 30,			March 31,
		2013			2013
	Components of Property and Equipment
	Machinery	$	1,672		$	1,580
	Computer equipment	8,788			6,559
	Furniture and fixtures	1,808			1,510
	Leasehold improvements	4,732			4,713
		17,000			14,362
	Accumulated depreciation	(5,744		)	(4,466		)
	Property and equipment, net	$	11,256		$	9,896

Goodwill_Tables

Goodwill (Tables)	6 Months Ended
	Sep. 30, 2013
Goodwill [Abstract]	'
Reconciliation of the Activity Affecting Goodwill	'
	A reconciliation of the activity affecting goodwill by operating segment is as follows:
	(In thousands)	OTC		Household		Consolidated
		Healthcare		Cleaning
	Balance — March 31, 2013	$	160,157	$	7,389	$	167,546
	Additions	23,122		—		23,122
	Effects of foreign currency exchange rates	390		—		390
	Balance — September 30, 2013	$	183,669	$	7,389	$	191,058

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2013
Intangible Assets [Abstract]	'
Reconciliation of the Activity Affecting Intangible Assets	'
	A reconciliation of the activity affecting intangible assets is as follows:
	(In thousands)	Indefinite			Finite Lived		Non Compete			Totals
		Lived			Trademarks		Agreement
		Trademarks
	Gross Carrying Amounts
	Balance — March 31, 2013	$	1,243,718		$	203,066	$	158		$	1,446,942
	Additions	29,845			1,657		—			31,502
	Reductions	—			—		(158		)	(158		)
	Effects of foreign currency exchange rates	512			29		—			541
	Balance — September 30, 2013	$	1,274,075		$	204,752	$	—		$	1,478,827
	Accumulated Amortization
	Balance — March 31, 2013	$	—		$	73,544	$	158		$	73,702
	Additions	—			5,423		—			5,423
	Reductions	—			—		(158		)	(158		)
	Balance — September 30, 2013	$	—		$	78,967	$	—		$	78,967
	Intangible assets, net - September 30, 2013	$	1,274,075		$	125,785	$	—		$	1,399,860
Schedule of Expected Amortization Expense	'
	At September 30, 2013, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:
	(In thousands)
	Year Ending March 31,		Amount
	2014 (Remaining six months ending March 31, 2014)		$	4,820
	2015		8,951
	2016		8,951
	2017		8,951
	2018		8,951
	Thereafter		85,161
			$	125,785

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Other Accrued Liabiltiies	'
	Other accrued liabilities consist of the following:
	(In thousands)	September 30,		March 31,
		2013		2013
	Accrued marketing costs	$	14,223	$	17,187
	Accrued compensation costs	3,781		8,847
	Accrued broker commissions	2,137		1,028
	Income taxes payable	350		493
	Accrued professional fees	1,146		1,846
	Deferred rent	1,311		1,268
	Accrued lease termination costs	341		729
	Other accrued liabilities	12		—
		$	23,301	$	31,398

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt	'
	Long-term debt consists of the following, as of the dates indicated:
	(In thousands, except percentages)	September 30,			March 31,
		2013			2013
	2012 Senior Notes bearing interest at 8.125%, with interest only payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	$	250,000		$	250,000
	2012 Term Loan bearing interest at the Company's option at either a base rate plus applicable margin with a floor of 2.00% or LIBOR with a floor of 1.00%, due on January 31, 2019.	437,500			445,000
	2012 ABL Revolver bearing interest at the Company's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	47,500			33,000
	2010 Senior Notes bearing interest at 8.25%, with interest only payable on April 1 and October 1 of each year. The 2010 Senior Notes mature on April 1, 2018.	250,000			250,000
		985,000			978,000
	Less: unamortized discount	(6,302		)	(7,100		)
	Long-term debt, net of unamortized discount	$	978,698		$	970,900
Aggregate Future Principal Payments	'
	Aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the 2010 Senior Notes and the 2012 Senior Notes are as follows:
	(In thousands)
	Year Ending March 31,	Amount
	2014 (remaining six months ending March 31, 2014)	$	—
	2015	—
	2016	—
	2017	47,500
	2018	—
	Thereafter	937,500
		$	985,000

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	AOCI consisted of the following at September 30, 2013 and March 31, 2013:
		September 30,		March 31,
	(In thousands)	2013		2013
	Components of Accumulated Other Comprehensive Income (Loss)
	Cumulative translation adjustment	$	1,019	$	(104	)
	Total accumulated other comprehensive income (loss)	$	1,019	$	(104	)

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Earnings Per Share	'
	The following table sets forth the computation of basic and diluted earnings per share:
		Three Months Ended September 30,				Six Months Ended September 30,
	(In thousands, except per share data)	2013		2012		2013		2012
	Numerator
	Net income	$	32,792	$	19,244	$	53,484	$	33,899
	Denominator
	Denominator for basic earnings per share — weighted average shares outstanding	51,463		50,364		51,343		50,353
	Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	756		861		787		813
	Denominator for diluted earnings per share	52,219		51,225		52,130		51,166
	Earnings per Common Share:
	Basic net earnings per share	$	0.64	$	0.38	$	1.04	$	0.67
	Diluted net earnings per share	$	0.63	$	0.38	$	1.03	$	0.66

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Restricted Shares	'
	A summary of the Company's restricted shares and restricted stock units granted under the Plan is presented below:
					Weighted-
			Shares		Average
			(in thousands)		Grant-Date
	Restricted Shares and Restricted Stock Units				Fair Value
	Six months ended September 30, 2012:
	Outstanding at March 31, 2012		363.4		$	9.92
	Granted		128.9		13.59
	Vested and issued		(27.0	)	7.16
	Forfeited		(4.3	)	11.06
	Outstanding at September 30, 2012		461		11.1
	Vested at September 30, 2012		70.4		8.52
	Six months ended September 30, 2013:
	Outstanding at March 31, 2013		421.3		$	11.01
	Granted		120.6		30.19
	Vested and issued		(54.7	)	8.11
	Forfeited		(3.6	)	13.24
	Outstanding at September 30, 2013		483.6		16.11
	Vested at September 30, 2013		83.1		9.63
Stock Options, Valuation Assumptions	'
		Six Months Ended September 30,
		2013			2012
	Expected volatility	48		%	44		%
	Expected dividends	$	—		$	—
	Expected term in years	6			6.5
	Risk-free rate	1.3		%	1.2		%
Stock Option Activity	'
	A summary of option activity under the Plan is as follows:
					Weighted-			Weighted-	Aggregate
					Average			Average	Intrinsic
			Shares		Exercise			Remaining	Value
			(in thousands)		Price			Contractual	(in thousands)
	Options							Term
	Six months ended September 30, 2012:
	Outstanding at March 31, 2012		1,745.40		$	8.44
	Granted		444.9		13.36
	Exercised		(6.8	)	11.84
	Forfeited or expired		(11.7	)	10.99
	Outstanding at September 30, 2012		2,171.80		9.43			7.6	$	16,602
	Exercisable at September 30, 2012		1,027.70		8.39			6.9	7,132
	Six months ended September 30, 2013:
	Outstanding at March 31, 2013		1,386.40		$	10.43
	Granted		227.7		29.94
	Exercised		(539.4	)	9.54
	Forfeited or expired		(8.0	)	13.24
	Outstanding at September 30, 2013		1,066.70		15.02			6.5	$	16,110
	Exercisable at September 30, 2013		225.5		11.42			7.7	4,216

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	The following summarizes future minimum lease payments for our operating leases as of September 30, 2013:
	(In thousands)
	Year Ending March 31,	Facilities		Equipment		Total
	2014 (Remaining six months ending March 31, 2014)	$	1,024	$	82	$	1,106
	2015	1,049		136		1,185
	2016	994		135		1,129
	2017	1,023		68		1,091
	2018	1,044		—		1,044
	Thereafter	—		—		—
		$	5,134	$	421	$	5,555
Unrecorded Unconditional Purchase Obligations Disclosure	'
	Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.
	(In thousands)
	Year Ending March 31,	Amount
	2014 (Remaining six months ending March 31, 2014)	$	564
	2015	1,105
	2016	1,074
	2017	1,044
	2018	1,013
	Thereafter	1,542
		$	6,342

Business_Segments_Tables

Business Segments (Tables)	6 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Information about our Operating and Reportable Segments	'
	The tables below summarize information about our operating and reportable segments.
		Three Months Ended September 30, 2013										Six Months Ended September 30, 2013
	(In thousands)	OTC			Household			Consolidated				OTC		Household		Consolidated
		Healthcare			Cleaning							Healthcare		Cleaning
	Net sales	$	142,454		$	24,550		$	167,004			$	265,222	$	43,883	$	309,105
	Other revenues	155			1,283			1,438				312		1,996		2,308
	Total revenues	142,609			25,833			168,442				265,534		45,879		311,413
	Cost of sales	55,325			18,398			73,723				100,336		32,875		133,211
	Gross profit	87,284			7,435			94,719				165,198		13,004		178,202
	Advertising and promotion	25,313			731			26,044				43,545		1,639		45,184
	Contribution margin	$	61,971		$	6,704		68,675				$	121,653	$	11,365	133,018
	Other operating expenses							14,913								29,815
	Operating income							53,762								103,203
	Other expense							16,439								32,344
	Income before income taxes							37,323								70,859
	Provision for income taxes							4,531								17,375
	Net income							$	32,792							$	53,484
		Three Months Ended September 30, 2012										Six Months Ended September 30, 2012
	(In thousands)	OTC			Household			Consolidated				OTC		Household		Consolidated
		Healthcare			Cleaning							Healthcare		Cleaning
	Net sales	$	137,771		$	23,552		$	161,323			$	263,775	$	43,468	$	307,243
	Other revenues	164			368			532				345		1,264		1,609
	Total revenues	137,935			23,920			161,855				264,120		44,732		308,852
	Cost of sales	53,469			17,841			71,310				100,868		33,835		134,703
	Gross profit	84,466			6,079			90,545				163,252		10,897		174,149
	Advertising and promotion	22,046			1,462			23,508				39,899		3,934		43,833
	Contribution margin	$	62,420		$	4,617		67,037				$	123,353	$	6,963	130,316
	Other operating expenses							15,881								35,327
	Operating income							51,156								94,989
	Other expense							19,660								39,508
	Income before income taxes							31,496								55,481
	Provision for income taxes							12,252								21,582
	Net income							$	19,244							$	33,899
Information about our Revenues from Similar Product Groups	'
	The table below summarizes information about our revenues from similar product groups.
		Three Months Ended September 30,					Six Months Ended September 30,
	(In thousands)	2013		2012			2013			2012
	Analgesics	$	30,508	$	26,106		$	58,731		$	53,781
	Cough & Cold	33,636		32,969			55,218			56,773
	Gastrointestinal	22,814		25,329			44,651			49,533
	Eye & Ear Care	21,417		21,700			44,119			43,407
	Dermatologicals	16,494		15,600			30,426			30,082
	Oral Care	13,278		12,549			24,437			23,079
	Other OTC	4,462		3,682			7,952			7,465
	Total OTC Healthcare Segment	142,609		137,935			265,534			264,120
	Household Cleaning Segment	25,833		23,920			45,879			44,732
	Consolidated Total Revenues	$	168,442	$	161,855		$	311,413		$	308,852
Allocation of Long-Term Assets to Segments	'
	At September 30, 2013, substantially all of our long-term assets were located in the United States and have been allocated to the operating segments as follows:
	(In thousands)	OTC			Household			Consolidated
		Healthcare			Cleaning
	Goodwill	$	183,669		$	7,389		$	191,058
	Intangible assets
	Indefinite-lived	1,154,255			119,820			1,274,075
	Finite-lived	98,746			27,039			125,785
		1,253,001			146,859			1,399,860
		$	1,436,670		$	154,248		$	1,590,918

Condensed_Consolidating_Financ1

Condensed Consolidating Financial Statements (Tables)	6 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Condensed Consolidating Statements of Income and Comprehensive Income	'
	Condensed Consolidating Statements of Income and Comprehensive Income
	Three Months Ended September 30, 2013
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	25,391		$	134,164		$	7,449		$	—		$	167,004
	Other revenues	—			67			1,431			668			(728		)	1,438
	Total revenues	—			25,458			135,595			8,117			(728		)	168,442
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			9,338			61,513			3,600			(728		)	73,723
	Gross profit	—			16,120			74,082			4,517			—			94,719
	Operating Expenses
	Advertising and promotion	—			3,748			20,899			1,397			—			26,044
	General and administrative	891			1,481			7,781			1,466			—			11,619
	Depreciation and amortization	517			143			2,589			45			—			3,294
	Total operating expenses	1,408			5,372			31,269			2,908			—			40,957
	Operating income (loss)	(1,408		)	10,748			42,813			1,609			—			53,762
	Other (income) expense
	Interest income	(12,778		)	(14,005		)	(710		)	(22		)	27,490			(25		)
	Interest expense	8,687			16,464			18,093			710			(27,490		)	16,464
	Equity in income of subsidiaries	(30,922		)	27,475			(1,189		)	—			4,636			—
	Total other (income) expense	(35,013		)	29,934			16,194			688			4,636			16,439
	Income before income taxes	33,605			(19,186		)	26,619			921			(4,636		)	37,323
	Provision (benefit) for income taxes	813			922			3,064			(268		)	—			4,531
	Net income (loss)	$	32,792		$	(20,108	)	$	23,555		$	1,189		$	(4,636	)	$	32,792
	Comprehensive income, net of tax:
	Currency translation adjustments	1,122			—			—			1,122			(1,122		)	1,122
	Total other comprehensive income (loss)	1,122			—			—			1,122			(1,122		)	1,122
	Comprehensive income (loss)	$	33,914		$	(20,108	)	$	23,555		$	2,311		$	(5,758	)	$	33,914
	Condensed Consolidating Statements of Income and Comprehensive Income
	Six Months Ended September 30, 2013
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	49,650		$	250,783		$	8,672		$	—		$	309,105
	Other revenues	—			135			2,294			1,102			(1,223		)	2,308
	Total revenues	—			49,785			253,077			9,774			(1,223		)	311,413
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			18,796			111,502			4,136			(1,223		)	133,211
	Gross profit	—			30,989			141,575			5,638			—			178,202
	Operating Expenses
	Advertising and promotion	—			7,188			36,392			1,604			—			45,184
	General and administrative	2,390			3,124			16,238			1,501			—			23,253
	Depreciation and amortization	1,034			285			5,184			59			—			6,562
	Total operating expenses	3,424			10,597			57,814			3,164			—			74,999
	Operating income (loss)	(3,424		)	20,392			83,761			2,474			—			103,203
	Other (income) expense
	Interest income	(24,991		)	(28,328		)	(710		)	(24		)	54,025			(28		)
	Interest expense	17,294			32,372			36,021			710			(54,025		)	32,372
	Equity in income of subsidiaries	(50,777		)	12,922			(1,868		)	—			39,723			—
	Total other (income) expense	(58,474		)	16,966			33,443			686			39,723			32,344
	Income before income taxes	55,050			3,426			50,318			1,788			(39,723		)	70,859
	Provision (benefit) for income taxes	1,566			4,009			11,880			(80		)	—			17,375
	Net income (loss)	$	53,484		$	(583	)	$	38,438		$	1,868		$	(39,723	)	$	53,484
	Comprehensive income, net of tax:
	Currency translation adjustments	1,123			—			—			1,123			(1,123		)	1,123
	Total other comprehensive income (loss)	1,123			—			—			1,123			(1,123		)	1,123
	Comprehensive income (loss)	$	54,607		$	(583	)	$	38,438		$	2,991		$	(40,846	)	$	54,607
	Condensed Consolidating Statements of Income and Comprehensive Income
Three Months Ended September 30, 2012
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	26,727		$	133,277		$	1,319		$	—		$	161,323
Other revenues	—			74			524			519			(585		)	532
Total revenues	—			26,801			133,801			1,838			(585		)	161,855
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			10,175			61,175			545			(585		)	71,310
Gross profit	—			16,626			72,626			1,293			—			90,545
Operating Expenses
Advertising and promotion	—			2,777			20,410			321			—			23,508
General and administrative	895			1,707			9,977			6			—			12,585
Depreciation and amortization	137			139			3,004			16			—			3,296
Total operating expenses	1,032			4,623			33,391			343			—			39,389
Operating income (loss)	(1,032		)	12,003			39,235			950			—			51,156
Other (income) expense
Interest income	(12,242		)	(11,061		)	—			(54		)	23,354			(3		)
Interest expense	8,746			28,410			5,861			—			(23,354		)	19,663
Equity in income of subsidiaries	(17,738		)	(20,995		)	(780		)	—			39,513			—
Total other (income) expense	(21,234		)	(3,646		)	5,081			(54		)	39,513			19,660
Income before income taxes	20,202			15,649			34,154			1,004			(39,513		)	31,496
Provision (benefit) for income taxes	958			(2,080		)	12,983			391			—			12,252
Net income	$	19,244		$	17,729		$	21,171		$	613		$	(39,513	)	$	19,244
Comprehensive income, net of tax:
Currency translation adjustments	66			—			—			66			(66		)	66
Total other comprehensive income	66			—			—			66			(66		)	66
Comprehensive income	$	19,310		$	17,729		$	21,171		$	679		$	(39,579	)	$	19,310
Condensed Consolidating Statements of Income and Comprehensive Income
Six Months Ended September 30, 2012
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	49,949		$	254,934		$	2,360		$	—		$	307,243
Other revenues	—			141			1,586			994			(1,112		)	1,609
Total revenues	—			50,090			256,520			3,354			(1,112		)	308,852
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			18,616			116,210			989			(1,112		)	134,703
Gross profit	—			31,474			140,310			2,365			—			174,149
Operating Expenses
Advertising and promotion	—			5,884			37,330			619			—			43,833
General and administrative	2,724			3,436			22,067			509			—			28,736
Depreciation and amortization	269			280			6,009			33			—			6,591
Total operating expenses	2,993			9,600			65,406			1,161			—			79,160
Operating income (loss)	(2,993		)	21,874			74,904			1,204			—			94,989
Other (income) expense
Interest income	(24,370		)	(22,021		)	—			(101		)	46,487			(5		)
Interest expense	17,412			56,926			11,662			—			(46,487		)	39,513
Equity in income of subsidiaries	(31,476		)	(40,873		)	(913		)	—			73,262			—
Total other (income) expense	(38,434		)	(5,968		)	10,749			(101		)	73,262			39,508
Income before income taxes	35,441			27,842			64,155			1,305			(73,262		)	55,481
Provision (benefit) for income taxes	1,542			(5,069		)	24,601			508			—			21,582
Net income	$	33,899		$	32,911		$	39,554		$	797		$	(73,262	)	$	33,899
Comprehensive income, net of tax:
Currency translation adjustments	24			—			—			24			(24		)	24
Total other comprehensive income	24			—			—			24			(24		)	24
Comprehensive income	$	33,923		$	32,911		$	39,554		$	821		$	(73,286	)	$	33,923
Condensed Consolidating Balance Sheet	'
	Condensed Consolidating Balance Sheet
	September 30, 2013
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Assets
	Current assets
	Cash and cash equivalents	$	23,668		$	—		$	—		$	3,165		$	—		$	26,833
	Accounts receivable, net	133			12,879			63,667			3,855			—			80,534
	Inventories	—			13,139			45,401			3,395			—			61,935
	Deferred income tax assets	232			885			5,310			—			—			6,427
	Prepaid expenses and other current assets	2,286			240			4,396			411			(404		)	6,929
	Total current assets	26,319			27,143			118,774			10,826			(404		)	182,658
	Property and equipment, net	10,791			20			182			263			—			11,256
	Goodwill	—			66,007			101,539			23,512			—			191,058
	Intangible assets, net	—			193,128			1,174,410			32,322			—			1,399,860
	Other long-term assets	—			23,244			—			—			—			23,244
	Intercompany receivable	654,016			1,918,831			496,358			9,102			(3,078,307		)	—
	Investment in subsidiary	1,538,436			682,450			8,936			—			(2,229,822		)	—
	Total Assets	$	2,229,562		$	2,910,823		$	1,900,199		$	76,025		$	(5,308,533	)	$	1,808,076
	Liabilities and Stockholders' Equity
	Current liabilities
	Accounts payable	$	2,084		$	9,304		$	36,222		$	4,247		$	—		$	51,857
	Accrued interest payable	—			13,951			—			—			—			13,951
	Other accrued liabilities	6,476			1,804			13,096			2,329			(404		)	23,301
	Total current liabilities	8,560			25,059			49,318			6,576			(404		)	89,109
	Long-term debt
	Principal amount	—			985,000			—			—			—			985,000
	Less unamortized discount	—			(6,302		)	—			—			—			(6,302		)
	Long-term debt, net of unamortized discount	—			978,698			—			—			—			978,698
	Deferred income tax liabilities	—			54,679			143,970			72			—			198,721
	Long term liabilities	—			—			—			296			—			296
	Intercompany payable	1,679,749			435,445			928,333			34,780			(3,078,307		)	—
	Total Liabilities	1,688,309			1,493,881			1,121,621			41,724			(3,078,711		)	1,266,824
	Stockholders' Equity
	Preferred share rights	283			—			—			—			—			283
	Common stock	520			—			—			—			—			520
	Additional paid-in capital	410,664			1,337,706			658,799			23,815			(2,020,320		)	410,664
	Treasury stock, at cost - 191 shares	(965		)	—			—			—			—			(965		)
	Accumulated other comprehensive income, net of tax	1,019			—			—			1,019			(1,019		)	1,019
	Retained earnings (accumulated deficit)	129,731			79,236			119,780			9,467			(208,483		)	129,731
	Total Stockholders' Equity	541,252			1,416,942			778,579			34,301			(2,229,822		)	541,252
	Total Liabilities and Stockholders' Equity	$	2,229,561		$	2,910,823		$	1,900,200		$	76,025		$	(5,308,533	)	$	1,808,076
	Condensed Consolidating Balance Sheet
	March 31, 2013
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Assets
	Current assets
	Cash and cash equivalents	$	14,720		$	—		$	—		$	950		$	—		$	15,670
	Accounts receivable, net	21			13,875			58,345			812			—			73,053
	Inventories	—			11,164			48,474			563			—			60,201
	Deferred income tax assets	218			855			5,276			—			—			6,349
	Prepaid expenses and other current assets	4,942			93			3,609			256			—			8,900
	Total current assets	19,901			25,987			115,704			2,581			—			164,173
	Property and equipment, net	9,609			34			253			—			—			9,896
	Goodwill	—			66,007			101,539			—			—			167,546
	Intangible assets, net	—			193,396			1,179,524			320			—			1,373,240
	Other long-term assets	—			24,944			—			—			—			24,944
	Intercompany receivable	653,049			1,911,573			415,587			7,316			(2,987,525		)	—
Investment in subsidiary	1,429,775			638,611			7,067			—			(2,075,453		)	—
Total Assets	$	2,112,334		$	2,860,552		$	1,819,674		$	10,217		$	(5,062,978	)	$	1,739,799
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,601		$	10,600		$	37,695		$	480		$	—		$	51,376
Accrued interest payable	—			13,894			—			—			—			13,894
Other accrued liabilities	12,694			1,684			16,107			913			—			31,398
Total current liabilities	15,295			26,178			53,802			1,393			—			96,668
Long-term debt
Principal amount	—			978,000			—			—			—			978,000
Less unamortized discount	—			(7,100		)	—			—			—			(7,100		)
Long-term debt, net of unamortized discount	—			970,900			—			—			—			970,900
Deferred income tax liabilities	—			55,291			138,924			73			—			194,288
Intercompany payable	1,619,096			447,419			920,865			145			(2,987,525		)	—
Total Liabilities	1,634,391			1,499,788			1,113,591			1,611			(2,987,525		)	1,261,856
Stockholders' Equity
Preferred share rights	283			—			—			—			—			283
Common stock	513			—			—			—			—			513
Additional paid-in capital	401,691			1,280,945			624,742			1,111			(1,906,798		)	401,691
Treasury stock, at cost - 181 shares	(687		)	—			—			—			—			(687		)
Accumulated other comprehensive loss, net of tax	(104		)	—			—			(104		)	104			(104		)
Retained earnings (accumulated deficit)	76,247			79,819			81,341			7,599			(168,759		)	76,247
Total Stockholders' Equity	477,943			1,360,764			706,083			8,606			(2,075,453		)	477,943
Total Liabilities and Stockholders' Equity	$	2,112,334		$	2,860,552		$	1,819,674		$	10,217		$	(5,062,978	)	$	1,739,799
Condensed Consolidating Statement of Cash Flows	'
	Condensed Consolidating Statement of Cash Flows
	Six Months Ended September 30, 2013
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Operating Activities
	Net income (loss)	$	53,484		$	(583	)	$	38,438		$	1,868		$	(39,723	)	$	53,484
	Adjustments to reconcile net income (loss) to net cash provided by operating activities:
	Depreciation and amortization	1,034			285			5,184			59			—			6,562
	Deferred income taxes	(14		)	(642		)	5,012			(1		)	—			4,355
	Amortization of deferred financing costs	—			1,975			—			—			—			1,975
	Stock-based compensation costs	2,487			—			—			—			—			2,487
	Amortization of debt discount	—			798			—			—			—			798
	Gain on sale of assets	—			—			(3		)	—			—			(3		)
	Equity in income of subsidiaries	(50,777		)	12,922			(1,868		)	—			39,723			—
	Changes in operating assets and liabilities, net of effects from acquisitions:
	Accounts receivable	(112		)	996			(5,322		)	(1,274		)	—			(5,712		)
	Inventories	—			(1,975		)	3,073			(277		)	—			821
	Prepaid expenses and other current assets	2,656			(147		)	(787		)	493			404			2,619
	Accounts payable	(517		)	(1,296		)	(1,473		)	2,161			—			(1,125		)
	Accrued liabilities	(6,218		)	177			(3,011		)	(1,207		)	(404		)	(10,663		)
	Net cash provided by operating activities	2,023			12,510			39,243			1,822			—			55,598
	Investing Activities
	Purchases of property and equipment	(2,216		)	—			—			(103		)	—			(2,319		)
	Proceeds from the sale of property and equipment	—			—			3			—			—			3
	Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
	Intercompany activity, net	—			(55,215		)	—			55,215			—			—
	Net cash provided by (used in) investing activities	(2,216		)	(55,215		)	3			(103		)	—			(57,531		)
	Financing Activities
	Repayments of long-term debt	—			(7,500		)	—			—			—			(7,500		)
	Repayments under revolving credit agreement	—			(35,500		)	—			—			—			(35,500		)
	Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
	Payment of deferred financing costs	—			(275		)	—			—			—			(275		)
	Proceeds from exercise of stock options	5,143			—			—			—			—			5,143
	Excess tax benefits from share-based awards	1,350			—			—			—			—			1,350
	Shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
	Intercompany activity, net	2,926			35,980			(39,246		)	340			—			—
	Net cash provided by (used in) financing activities	9,141			42,705			(39,246		)	340			—			12,940
	Effect of exchange rate changes on cash and cash equivalents	—			—			—			156			—			156
	Increase in cash and cash equivalents	8,948			—			—			2,215			—			11,163
	Cash - beginning of period	14,720			—			—			950			—			15,670
	Cash - end of period	$	23,668		$	—		$	—		$	3,165		$	—		$	26,833
	Condensed Consolidating Statement of Cash Flows
	Six Months Ended September 30, 2012
	(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
	Operating Activities
	Net income (loss)	$	33,899		$	32,911		$	39,554		$	797		$	(73,262	)	$	33,899
	Adjustments to reconcile net income (loss) to net cash provided by operating activities:
	Depreciation and amortization	269			280			6,009			33			—			6,591
	Deferred income taxes	109			1,676			10,612			(6		)	—			12,391
	Amortization of deferred financing costs	—			2,060			—			—			—			2,060
	Stock-based compensation costs	1,973			—			—			—			—			1,973
	Lease termination costs	975			—			—			—			—			975
	Amortization of debt discount	—			812			—			—			—			812
	Loss on disposal of equipment	30			—			21			—			—			51
	Equity in income of subsidiaries	(31,476		)	(40,873		)	(913		)	—			73,262			—
	Changes in operating assets and liabilities, net of effects from acquisitions:
	Accounts receivable	(117		)	(1,935		)	(21,910		)	(568		)	—			(24,530		)
	Inventories	—			205			(3,319		)	210			—			(2,904		)
	Prepaid expenses and other current assets	6,259			(48		)	(980		)	325			—			5,556
	Accounts payable	(2,394		)	2,759			14,109			676			—			15,150
	Accrued liabilities	(2,516		)	424			10,229			213			—			8,350
Net cash provided by (used in) operating activities	7,011			(1,729		)	53,412			1,680			—			60,374
Investing Activities
Purchases of property and equipment	(5,266		)	—			—			—			—			(5,266		)
Proceeds from sale of property and equipment	—			—			15			—			—			15
Acquisition of GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash provided by (used in) investing activities	(5,492		)	—			15			—			—			(5,477		)
Financing Activities
Repayment of long-term debt	—			(70,000		)	—			—			—			(70,000		)
Repayments under revolving credit agreement	—			(8,000		)	—			—			—			(8,000		)
Borrowings under revolving credit agreement	—			33,000			—			—			—			33,000
Proceeds from exercise of stock options	80			—			—			—			—			80
Intercompany activity, net	7,902			46,729			(53,427		)	(1,204		)	—			—
Net cash provided by (used in) financing activities	7,982			1,729			(53,427		)	(1,204		)	—			(44,920		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			14			—			14
Increase in cash and cash equivalents	9,501			—			—			490			—			9,991
Cash - beginning of period	18,221			—			—			794			—			19,015
Cash - end of period	$	27,722		$	—		$	—		$	1,284		$	—		$	29,006

Business_and_Basis_of_Presenta3

Business and Basis of Presentation (Property and Equipment) (Details)	6 Months Ended
	Sep. 30, 2013
Machinery	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, useful lives	'5 years
Computer equipment	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, useful lives	'3 years
Furniture and fixtures	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, useful lives	'7 years
Leasehold improvements	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, useful lives	'	[1]
[1]	Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Business_and_Basis_of_Presenta4

Business and Basis of Presentation (Intangible Assets) (Details)	6 Months Ended
	Sep. 30, 2013
Minimum	'
Finite-Lived Intangible Assets [Line Items]	'
Intangible assets, useful lives	'3 years
Maximum	'
Finite-Lived Intangible Assets [Line Items]	'
Intangible assets, useful lives	'30 years

Business_and_Basis_of_Presenta5

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'
Ownership percentage	100.00%	'	100.00%	'
Term of original maturities, cash equivalents, up to and including	'	'	'3 months	'
Shipping costs, and handling and storage costs	$9.10	$7.30	$15.70	$15.50

Acquisitions_Care_Pharmaceutic

Acquisitions (Care Pharmaceuticals Pty Ltd.) (Details) (USD $)	6 Months Ended		6 Months Ended
	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Jul. 02, 2013
			Care	Care
Purchase Price	'	'	'	'
Cash acquired	'	'	'	$1,546,000
Accounts receivable, net	'	'	'	1,658,000
Inventories	'	'	'	2,465,000
Prepaids and other current assets	'	'	'	647,000
Property, plant and equipment, net	'	'	'	163,000
Goodwill	191,058,000	167,546,000	'	23,122,000
Intangible assets	'	'	'	31,502,000
Total assets acquired	'	'	'	61,103,000
Accounts payable	'	'	'	1,537,000
Accrued expenses	'	'	'	2,505,000
Other long term liabilities	'	'	'	300,000
Total liabilities assumed	'	'	'	4,342,000
Net assets acquired	'	'	'	56,761,000
Finite-lived intangibles	'	'	'	1,700,000
Indefinite-lived intangible assets	'	'	'	$29,800,000
Purchased amortizable intangible assets, weighted average useful life	'	'	'15 years 1 month 6 days	'
Amortizable intangible assets, weighted average remaining life	'14 years 2 months 1 day	'	'14 years 11 months 0 days	'

Acquisitions_OTC_Brands_from_G

Acquisitions (OTC Brands from GlaxoSmithKline) (Details) (USD $)

6 Months Ended

0 Months Ended

2 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2013

Dec. 20, 2011

31-May-12

Sep. 30, 2013

Mar. 31, 2013

Mar. 31, 2012

Jan. 31, 2012

Apr. 30, 2012

Mar. 30, 2012

31-May-12

Jan. 31, 2012

Jun. 30, 2012

GSK Brands

GSK Brands

GSK Brands

GSK Brands

GSK Brands

GSK Brands I

GSK Brands I

GSK Brands II

GSK Brands II

GSK

GSK

agreement

brand

brand

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of purchase agreements

'

'

'

2

'

'

'

'

'

'

'

'

'

'

Number of brands acquired

'

'

'

17

'

'

'

'

15

'

'

'

'

'

Payments to acquire businesses

'

'

'

$660,000,000

'

'

'

'

$615,000,000

'

$45,000,000

'

'

'

Post-closing adjustments added to purchase price

0

226,000

'

'

3,000,000

'

'

'

'

2,800,000

'

200,000

'

'

Transitional services agreement, estimated monthly costs to be incurred

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

Transitional services agreement, actual costs incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

6,800,000

Goodwill, expected tax deductible amount

'

'

'

'

'

'

20,200,000

'

'

'

'

'

'

'

Non-amortizable intangible assets

'

'

'

'

'

'

556,900,000

'

'

'

'

'

'

'

Amortizable intangible assets

'

'

'

'

'

'

67,200,000

'

'

'

'

'

'

'

Purchased amortizable intangible assets, weighted average useful life

'

'

'

'

'

'19 years 3 months 18 days

'

'

'

'

'

'

'

'

Amortizable intangible assets, weighted average remaining life

'14 years 2 months 1 day

'

'

'

'

'17 years 6 months 0 days

'

'

'

'

'

'

'

'

Purchase Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories

'

'

'

'

'

'

'

15,070,000

14,820,000

'

250,000

'

'

'

Prepaids and other current assets

'

'

'

'

'

'

'

3,575,000

3,575,000

'

0

'

'

'

Trade names

'

'

'

'

'

'

'

624,149,000

542,892,000

'

81,257,000

'

'

'

Goodwill

191,058,000

'

167,546,000

'

'

'

'

20,232,000

17,401,000

'

2,831,000

'

'

'

Total purchase price

'

'

'

'

'

'

'

$663,026,000

$578,688,000

'

$84,338,000

'

'

'

Divestitures_Details

Divestitures (Details) (Sale of Phazyme Brand, USD $)	Oct. 31, 2012
In Thousands, unless otherwise specified
Sale of Phazyme Brand	'
Components of assets sold:	'
Inventory	$220
Prepaid expenses	100
Trade names	15,604
Goodwill	$6,382

Divestitures_Narrative_Details

Divestitures (Narrative) (Details) (Sale of Phazyme Brand, USD $)	0 Months Ended
In Millions, unless otherwise specified	Jan. 04, 2013	Oct. 31, 2012
Sale of Phazyme Brand	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'
Proceeds from the sale of the Phazyme brand	$0.60	$21.70

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	$88,697	$80,361
Less allowances for discounts, returns and uncollectible accounts	-8,163	-7,308
Accounts receivable, net	80,534	73,053
Trade Accounts Receivable	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	87,966	79,746
Other Receivables	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	$731	$615

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Inventory Disclosure [Abstract]	'	'
Packaging and raw materials	$1,034,000	$1,875,000
Finished goods	60,901,000	58,326,000
Inventories	61,935,000	60,201,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$2,200,000	$1,300,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	$17,000,000	'	$17,000,000	'	$14,362,000
Accumulated depreciation	-5,744,000	'	-5,744,000	'	-4,466,000
Property and equipment, net	11,256,000	'	11,256,000	'	9,896,000
Depreciation	500,000	400,000	1,100,000	600,000	'
Machinery	'	'	'	'	'
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	1,672,000	'	1,672,000	'	1,580,000
Computer equipment	'	'	'	'	'
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	8,788,000	'	8,788,000	'	6,559,000
Furniture and fixtures	'	'	'	'	'
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	1,808,000	'	1,808,000	'	1,510,000
Leasehold improvements	'	'	'	'	'
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	$4,732,000	'	$4,732,000	'	$4,713,000

Goodwill_Details

Goodwill (Details) (USD $)	6 Months Ended	3 Months Ended		3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Mar. 31, 2013
		OTC Healthcare	OTC Healthcare	Household Cleaning	Household Cleaning
Goodwill [Roll Forward]	'	'	'	'	'
Goodwill, net	$167,546	'	$160,157	'	$7,389
Additions	23,122	'	'	0	'
Goodwill, Translation Adjustments	390	390	'	0	'
Goodwill, net	$191,058	$183,669	$160,157	$7,389	$7,389

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Mar. 31, 2013
Indefinite-Lived Intangible Assets [Abstract]	'	'	'
Indefinite-lived intangibles, reductions	'	$0	'
Indefinite-lived intangibles, effects of foreign currency exchange rate	'	512	'
Indefinite-lived intangibles, ending balance	1,274,075	1,274,075	'
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Intangible assets, accumulated amortization, additions	2,700	5,423	'
Intangible Assets, Gross [Abstract]	'	'	'
Intangible assets, gross, beginning balance	'	1,446,942	'
Intangible assets, additions	'	31,502	'
Intangible assets, reductions	'	-158	'
Intangible assets, gross, ending balance	1,478,827	1,478,827	'
Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Intangible assets, accumulated amortization, beginning balance	'	73,702	'
Intangible assets, accumulated amortization, additions	2,700	5,423	'
Intangible assets, accumulated amortization, reductions	'	-158	'
Intangible assets, effects of foreign currency exchange rate	'	541	'
Intangible assets, accumulated amortization, ending balance	78,967	78,967	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net	125,785	125,785	'
Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net (excluding goodwill)	1,399,860	1,399,860	1,373,240
Indefinite Lived Trademarks	'	'	'
Indefinite-Lived Intangible Assets [Abstract]	'	'	'
Indefinite-lived intangibles, beginning balance	'	1,243,718	'
Indefinite-lived intangibles, additions	'	29,845	'
Indefinite-lived intangibles, ending balance	1,274,075	1,274,075	'
Finite Lived Trademarks	'	'	'
Finite-Lived Intangible Assets, Gross [Abstract]	'	'	'
Finite-lived intangibles, gross, beginning balance	'	203,066	'
Finite-lived intangibles, additions	'	1,657	'
Finite-lived intangibles, reductions	'	0	'
Finite-lived intangibles, effects of foreign currency exchange rate	'	29	'
Finite-lived intangibles, gross, ending balance	204,752	204,752	'
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Finite-lived intangibles, accumulated amortization, beginning balance	'	73,544	'
Intangible assets, accumulated amortization, additions	'	5,423	'
Finite-lived intangibles, accumulated amortization, reductions	'	0	'
Finite-lived intangibles, accumulated amortization, ending balance	78,967	78,967	'
Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Intangible assets, accumulated amortization, additions	'	5,423	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net	125,785	125,785	'
Noncompete Agreements	'	'	'
Finite-Lived Intangible Assets, Gross [Abstract]	'	'	'
Finite-lived intangibles, gross, beginning balance	'	158	'
Finite-lived intangibles, additions	'	0	'
Finite-lived intangibles, reductions	'	-158	'
Finite-lived intangibles, effects of foreign currency exchange rate	'	0	'
Finite-lived intangibles, gross, ending balance	0	0	'
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Finite-lived intangibles, accumulated amortization, beginning balance	'	158	'
Intangible assets, accumulated amortization, additions	'	0	'
Finite-lived intangibles, accumulated amortization, reductions	'	-158	'
Finite-lived intangibles, accumulated amortization, ending balance	0	0	'
Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Intangible assets, accumulated amortization, additions	'	0	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net	$0	$0	'

Intangible_Assets_Expected_Amo

Intangible Assets (Expected Amortization Expense) (Details) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, weighted average remaining period	'	'14 years 2 months 1 day
Amortization of intangible assets	$2,700	$5,423
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'	'
2014 (Remaining six months ending March 31, 2014)	4,820	4,820
2015	8,951	8,951
2016	8,951	8,951
2017	8,951	8,951
2018	8,951	8,951
Thereafter	85,161	85,161
Intangible assets, net	$125,785	$125,785
Minimum	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, useful lives	'	'3 years
Maximum	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, useful lives	'	'30 years

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accrued marketing costs	$14,223	$17,187
Accrued compensation costs	3,781	8,847
Accrued broker commissions	2,137	1,028
Income taxes payable	350	493
Accrued professional fees	1,146	1,846
Deferred rent	1,311	1,268
Accrued lease termination costs	341	729
Other accrued liabilities	12	0
Other accrued liabilities	$23,301	$31,398

LongTerm_Debt_Narrative_Detail

Long-Term Debt (Narrative) (Details) (USD $)

6 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

6 Months Ended

6 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2013

Jan. 31, 2012

Sep. 30, 2013

Jan. 31, 2012

Jan. 31, 2012

Jun. 30, 2013

Sep. 30, 2012

Jan. 31, 2012

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Nov. 01, 2010

Mar. 24, 2010

Sep. 30, 2013

Mar. 31, 2011

Mar. 24, 2010

Mar. 24, 2010

Mar. 24, 2010

Mar. 24, 2010

Mar. 24, 2010

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Nov. 01, 2010

Mar. 31, 2013

Feb. 21, 2013

Feb. 21, 2013

Jan. 31, 2012

Sep. 30, 2013

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Sep. 30, 2013

2012 Senior Notes

2012 Senior Notes

Term Loan and ABL Revolver 2012

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Revolving Credit Facility

2010 Revolving Credit Facility

2010 Revolving Credit Facility

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2010 Senior Notes

2010 Senior Notes

2010 Senior Notes

2010 Senior Notes

2010 Senior Notes

2010 Senior Notes

2010 Senior Notes

2010 Senior Notes

2010 Senior Notes

2012 Senior Notes

2012 Senior Notes

2012 Senior Notes

2012 Senior Notes

2010 Term Loan

Amended 2012 Term Loan

Amended 2012 Term Loan

Amended 2012 Term Loan

2012 Term Loan

2012 Term Loan

2012 Term Loan

2012 Term Loan

2012 Term Loan

2012 Term Loan

2012 ABL Revolver

LIBOR

LIBOR

LIBOR

Base Rate

Base Rate

Base Rate

Base Rate

Base Rate

Prior To April 1, 2014

Twelve Months Beginning April 1, 2014

Twelve Months Beginning April 1, 2015

On or After April 1, 2016

Prior to April 1, 2013

Prior To April 1, 2014

Prior to April 1, 2013

Upon Change in Control

LIBOR

LIBOR

Base Rate

Base Rate

Base Rate

Minimum

Maximum

Minimum

Maximum

Federal Funds Rate

LIBOR

Minimum

Federal Funds Rate

LIBOR

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$150,000,000

'

'

'

'

'

'

'

$250,000,000

'

'

'

'

'

'

'

$660,000,000

'

'

'

'

'

'

Debt instrument, stated interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.25%

'

'

'

'

'

'

'

8.13%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, increase, additional borrowings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

115,000,000

'

'

'

'

'

'

'

'

'

'

Debt instrument, unamortized discount

6,302,000

'

7,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, unamortized premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of long-term debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,300,000

147,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

650,100,000

'

'

'

'

'

'

Debt instrument, effective interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of subsidiary owned

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs capitalized

'

'

'

'

'

12,600,000

20,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, maturity term

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

'

'

Line of credit facility, maximum borrowing capacity

'

'

'

'

'

'

'

'

'

50,000,000

95,000,000

'

75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Decrease in interest rate

'

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, increase in borrowing capacity

'

'

'

'

'

'

'

20,000,000

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, discount, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.50%

'

'

'

'

'

'

Debt instrument, basis spread on variable rate, fixed component

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

0.50%

1.00%

'

Debt instrument, basis spread on variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.75%

'

'

1.00%

'

'

'

'

Debt instrument, average interest rate during period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.80%

'

'

'

'

'

Debt instrument, quarterly payment, percent of original principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

Debt instrument, variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

1.75%

'

'

0.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, conditional variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

2.25%

'

1.00%

1.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, commitment fee percentage

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, conditional commitment fee percentage

'

'

'

'

'

'

'

'

'

0.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, interest rate at period end

'

'

'

'

'

'

'

'

'

'

'

2.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized debt issuance costs

23,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized debt issuance expense and discount

'

'

'

'

10,700,000

'

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,400,000

'

'

'

'

'

Debt instrument, redemption price, percentage of principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

104.13%

102.06%

100.00%

108.25%

'

100.00%

108.13%

101.00%

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, percentage of principal amount eligible for redemption

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of long-term debt

7,500,000

70,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,500,000

Debt Instrument, Reference Rate Floor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,400,000

'

'

'

'

'

'

'

'

'

LongTerm_Debt_Schedule_of_Long

Long-Term Debt (Schedule of Long-term Debt) (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013	Mar. 24, 2010
Debt Instrument [Line Items]	'	'	'
Long-term debt, gross	$985,000,000	$978,000,000	'
Less: unamortized discount	-6,302,000	-7,100,000	'
Long-term debt, net of unamortized discount	978,698,000	970,900,000	'
Senior Notes | 2012 Senior Notes	'	'	'
Debt Instrument [Line Items]	'	'	'
Long-term debt, gross	250,000,000	250,000,000	'
Senior Notes | 2010 Senior Notes	'	'	'
Debt Instrument [Line Items]	'	'	'
Long-term debt, gross	250,000,000	250,000,000	'
Less: unamortized discount	'	'	-2,200,000
Term Loans | 2012 Term Loan	'	'	'
Debt Instrument [Line Items]	'	'	'
Long-term debt, gross	437,500,000	445,000,000	'
Revolving Credit Facility | 2012 ABL Revolver	'	'	'
Debt Instrument [Line Items]	'	'	'
Long-term debt, gross	$47,500,000	$33,000,000	'

LongTerm_Debt_Maturities_of_Lo

Long-Term Debt (Maturities of Long-term Debt) (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Debt Disclosure [Abstract]	'	'
2014 (remaining six months ending March 31, 2014)	$0	'
2015	0	'
2016	0	'
2017	47,500,000	'
2018	0	'
Thereafter	937,500,000	'
Long-term debt, gross	$985,000,000	$978,000,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Senior Notes | 2012 Senior Notes | Carrying Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Loans payable, fair value disclosure	$250,000,000	'
Senior Notes | 2010 Senior Notes | Carrying Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Loans payable, fair value disclosure	250,000,000	'
Senior Notes | Nonrecurring | Fair Value, Inputs, Level 2 | 2012 Senior Notes | Market Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Loans payable, fair value disclosure	276,900,000	281,900,000
Senior Notes | Nonrecurring | Fair Value, Inputs, Level 2 | 2010 Senior Notes | Market Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Loans payable, fair value disclosure	266,300,000	271,900,000
Term Loans | 2012 Term Loan | Carrying Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Loans payable, fair value disclosure	437,500,000	445,000,000
Term Loans | Nonrecurring | Fair Value, Inputs, Level 2 | 2012 Term Loan | Market Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Loans payable, fair value disclosure	439,100,000	451,100,000
Revolving Credit Facility | 2012 ABL Revolver | Carrying Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Line of credit, fair value disclosure	$47,500,000	$33,000,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012
			Restricted Shares	Restricted Shares	Restricted Shares
Class of Stock [Line Items]	'	'	'	'	'
Common stock, shares authorized	250,000,000	250,000,000	'	'	'
Common stock, par value (in USD per share)	$0.01	$0.01	'	'	'
Preferred stock, shares authorized	5,000,000	5,000,000	'	'	'
Preferred stock, par value (in USD per share)	$0.01	$0.01	'	'	'
Voting rights, number of votes per common share owned	1	'	'	'	'
Restricted stock repurchased during period, shares	'	'	0	10,726	'
Restricted stock acquired, average cost per share	'	'	'	'	$25.96

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Components of AOCI) (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Accumulated Other Comprehensive Income [Abstract]	'	'
Cumulative translation adjustment	$1,019	($104)
Total accumulated other comprehensive income (loss)	$1,019	($104)

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator	'	'	'	'
Net income	$32,792	$19,244	$53,484	$33,899
Denominator	'	'	'	'
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	51,463	50,364	51,343	50,353
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors (in shares)	756	861	787	813
Denominator for diluted earnings per share (in shares)	52,219	51,225	52,130	51,166
Earnings per Common Share:	'	'	'	'
Basic net earnings per share (in USD per share)	$0.64	$0.38	$1.04	$0.67
Diluted net earnings per share (in USD per share)	$0.63	$0.38	$1.03	$0.66

Earnings_Per_Share_Antidilutiv

Earnings Per Share Antidilutive Securities (Details) (Outstanding Stock Awards)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Outstanding Stock Awards	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, shares (fewer than 0.1 million shares for the three and nine months ended December 31, 2012)	0.2	0.3	0.2	0.4

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

In Millions, except Share data, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

14-May-13

Sep. 30, 2013

14-May-13

Jun. 30, 2013

Sep. 30, 2013

14-May-13

14-May-13

Restricted Stock and Restricted Stock Units (RSUs)

Restricted Stock and Restricted Stock Units (RSUs)

Restricted Stock and Restricted Stock Units (RSUs)

Restricted Stock and Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Stock Options

Stock Options

Employee

Employee

Employee

Director

Director

Group One

Group Two

Minimum

Maximum

Minimum

Maximum

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Stock Options

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Employee

Employee

Restricted Stock Units (RSUs)

Restricted Stock Units (RSUs)

Share-based Compensation, Aggregate Disclosures:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan

5,000,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation costs charged against income

$1.30

$1.10

$2.50

$2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tax benefit recognized from share-based compensation expense

0.3

0.3

0.7

0.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Award vesting period

'

'

'

'

'

'

'3 years

'5 years

'

'

'3 years

'5 years

'

'3 years

'3 years

'

'1 year

'3 years

'3 years

Restricted common stock units granted in period, shares

'

'

'

'

120,600

128,900

'

'

'

'

'

'

113,637

'

'

7,004,000

'

55,637

58,000

Granted, weighted-average grant-date fair value (in USD per share)

'

'

'

'

$30.19

$13.59

'

'

$30.19

$13.59

'

'

'

'

'

'

'

'

'

Options, Additional Disclosures:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Award exercisability period, from date of grant

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'10 years

'

'

'

'

Options granted, shares

'

'

227,700

444,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted, weighted-average exercise price (in USD per share)

'

'

$29.94

$13.36

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted, weighted-average grant-date fair value (in USD per share)

'

'

$13.94

$6.03

'

'

'

'

'

'

'

'

'

'

$29.94

'

'

'

'

Percentage of options vesting annually

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.30%

'

'

'

33.30%

Options granted in period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

227,672

'

'

'

'

Options exercised, aggregate intrinsic value

'

'

12.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation costs related to nonvested awards

6.1

'

6.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation costs related to nonvested awards, weighted average period for recognition

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of vested shares

'

'

3.2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less than cash received from exercise of stock options

'

'

5.1

0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less than the tax benefit realized from exercise of stock options

'

'

$1.70

$0.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for issuance under the Plan

1,600,000

'

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBased_Compensation_Restri

Share-Based Compensation (Restricted Shares and Restricted Stock Units Activity) (Details) (Restricted Stock and Restricted Stock Units (RSUs), USD $)	6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Restricted Stock and Restricted Stock Units (RSUs)	'	'
Shares	'	'
Outstanding, beginning of period	421,300	363,400
Granted	120,600	128,900
Vested and issued	-54,700	-27,000
Forfeited	-3,600	-4,300
Outstanding, end of period	483,600	461,000
Vested, end of period	83,100	70,400
Weighted- Average Grant-Date Fair Value	'	'
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$11.01	$9.92
Granted, weighted-average grant-date fair value (in USD per share)	$30.19	$13.59
Vested and issued, weighted-average grant-date fair value (in USD per share)	$8.11	$7.16
Forfeited, weighted-average grant-date fair value (in USD per share)	$13.24	$11.06
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	$16.11	$11.10
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$9.63	$8.52

ShareBased_Compensation_Stock_

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) (Stock Options, USD $)	6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Stock Options	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected volatility	48.00%	44.00%
Expected dividends	$0	$0
Expected term in years	'6 years	'6 years 6 months
Risk-free rate	1.30%	1.20%

ShareBased_Compensation_Stock_1

Share-Based Compensation (Stock Option Activity) (Details) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Shares	'	'
Outstanding, beginning of period (in shares)	1,386,400	1,745,400
Granted (in shares)	227,700	444,900
Exercised (in shares)	-539,400	-6,800
Forfeited or expired (in shares)	-8,000	-11,700
Outstanding, end of period (in shares)	1,066,700	2,171,800
Exercisable, end of period (in shares)	225,500	1,027,700
Weighted- Average Exercise Price	'	'
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$10.43	$8.44
Granted, weighted-average exercise price (in USD per share)	$29.94	$13.36
Exercised, weighted-average exercise price (in USD per share)	$9.54	$11.84
Forfeited or expired, weighted-average exercise price (in USD per share)	$13.24	$10.99
Outstanding, end of period, weighted-average exercise price (in USD per share)	$15.02	$9.43
Exercisable, end of period, weighted-average exercise price (in USD per share)	$11.42	$8.39
Options, Additional Disclosures:	'	'
Outstanding, end of period, weighted-average remaining contractual term	'6 years 6 months	'7 years 7 months 0 days
Exercisable, end of period, weighted-average remaining contractual term	'7 years 8 months 12 days	'6 years 11 months 0 days
Outstanding, end of period, aggregate intrinsic value	$16,110	$16,602
Exercisable, end of period, aggregate intrinsic value	$4,216	$7,132

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'	'	'	'
Effective income tax rate	12.10%	38.90%	24.50%	38.90%	'
Income tax benefit adjustment	$9.10	'	$9.10	'	'
Net operating loss carryforwards	1.1	'	1.1	'	'
Operating loss carryforwards, limitation on use, annual amount	0.2	'	0.2	'	'
Uncertain tax liability	$1	'	$1	'	$1

Commitments_and_Contingencies_1

Commitments and Contingencies (Future Minimum Rental Payments) (Details) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended	1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	31-May-12	Sep. 30, 2013
					Facilities	New York	Arkansas	Equipment
Operating Leased Assets [Line Items]	'	'	'	'	'	'	'	'
Operating lease, term	'	'	'	'	'	'5 years 6 months	'3 years	'
2014 (Remaining six months ending March 31, 2014)	$1,106,000	'	$1,106,000	'	$1,024,000	'	'	$82,000
2015	1,185,000	'	1,185,000	'	1,049,000	'	'	136,000
2016	1,129,000	'	1,129,000	'	994,000	'	'	135,000
2017	1,091,000	'	1,091,000	'	1,023,000	'	'	68,000
2018	1,044,000	'	1,044,000	'	1,044,000	'	'	0
Thereafter	0	'	0	'	0	'	'	0
Total future minimum payments due	5,555,000	'	5,555,000	'	5,134,000	'	'	421,000
Operating leases, rent expense	$500,000	$300,000	$800,000	$600,000	'	'	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Long-term Supply Agreement) (Details) (Third-party Manufacturing, USD $)	0 Months Ended
In Thousands, unless otherwise specified	Nov. 01, 2009	Sep. 30, 2013
Third-party Manufacturing	'	'
Long-term Purchase Commitment [Line Items]	'	'
Supply agreement, term	'10 years	'
2014 (Remaining six months ending March 31, 2014)	'	$564
2015	'	1,105
2016	'	1,074
2017	'	1,044
2018	'	1,013
Thereafter	'	1,542
Total purchase commitment	'	$6,342

Concentrations_of_Risk_Details

Concentrations of Risk (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
			brand
Concentration Risk [Line Items]	'	'	'	'
Number of third-party manufacturers	50	61	50	61
Sales | Product Concentration Risk	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	41.80%	40.30%	43.00%	41.30%
Number of highest selling brands comprising group against which concentration risk is measured	'	'	5	'
Sales | Customer Concentration Risk	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	19.20%	16.30%	20.40%	18.10%
Number of customers exceeding concentration risk benchmark	'	'	1	1
Sales | Supplier Concentration Risk	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	'	'	77.90%	84.90%
Number of third-party manufacturers with long-term contracts	'	'	22	28
Accounts Receivable | Customer Concentration Risk	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	'	'	19.70%	'

Business_Segments_Information_

Business Segments (Information on Operating and Reportable Segments) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	$167,004	$161,323	$309,105	$307,243
Other revenues	1,438	532	2,308	1,609
Total revenues	168,442	161,855	311,413	308,852
Cost of sales	73,723	71,310	133,211	134,703
Gross profit	94,719	90,545	178,202	174,149
Advertising and promotion	26,044	23,508	45,184	43,833
Contribution margin	68,675	67,037	133,018	130,316
Other operating expenses	14,913	15,881	29,815	35,327
Operating income	53,762	51,156	103,203	94,989
Other expense	16,439	19,660	32,344	39,508
Income before income taxes	37,323	31,496	70,859	55,481
Provision for income taxes	4,531	12,252	17,375	21,582
Net income	32,792	19,244	53,484	33,899
OTC Healthcare	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	142,454	137,771	265,222	263,775
Other revenues	155	164	312	345
Total revenues	142,609	137,935	265,534	264,120
Cost of sales	55,325	53,469	100,336	100,868
Gross profit	87,284	84,466	165,198	163,252
Advertising and promotion	25,313	22,046	43,545	39,899
Contribution margin	61,971	62,420	121,653	123,353
Household Cleaning	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	24,550	23,552	43,883	43,468
Other revenues	1,283	368	1,996	1,264
Total revenues	25,833	23,920	45,879	44,732
Cost of sales	18,398	17,841	32,875	33,835
Gross profit	7,435	6,079	13,004	10,897
Advertising and promotion	731	1,462	1,639	3,934
Contribution margin	$6,704	$4,617	$11,365	$6,963
Geographic Concentration Risk | Sales | United States	'	'	'	'
Geographic Areas, Revenues from External Customers [Abstract]	'	'	'	'
Concentration risk, percentage	86.90%	89.30%	87.80%	90.30%
Geographic Concentration Risk | Sales | Canada	'	'	'	'
Geographic Areas, Revenues from External Customers [Abstract]	'	'	'	'
Concentration risk, percentage	7.20%	8.10%	7.60%	7.30%

Business_Segments_Revenue_by_P

Business Segments (Revenue by Product) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	$168,442	$161,855	$311,413	$308,852
OTC Healthcare	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	142,609	137,935	265,534	264,120
OTC Healthcare | Analgesics	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	30,508	26,106	58,731	53,781
OTC Healthcare | Cough & Cold	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	33,636	32,969	55,218	56,773
OTC Healthcare | Gastrointestinal	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	22,814	25,329	44,651	49,533
OTC Healthcare | Eye & Ear Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	21,417	21,700	44,119	43,407
OTC Healthcare | Dermatologicals	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	16,494	15,600	30,426	30,082
OTC Healthcare | Oral Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	13,278	12,549	24,437	23,079
OTC Healthcare | Other OTC	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	4,462	3,682	7,952	7,465
Household Cleaning	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	$25,833	$23,920	$45,879	$44,732

Business_Segments_Assets_by_Se

Business Segments (Assets by Segment) (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Goodwill	$191,058	$167,546
Indefinite-lived intangibles	1,274,075	'
Finite-lived intangibles	125,785	'
Intangible assets, net (excluding goodwill)	1,399,860	1,373,240
Intangible assets, net (including goodwill)	1,590,918	'
OTC Healthcare	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Goodwill	183,669	160,157
Indefinite-lived intangibles	1,154,255	'
Finite-lived intangibles	98,746	'
Intangible assets, net (excluding goodwill)	1,253,001	'
Intangible assets, net (including goodwill)	1,436,670	'
Household Cleaning	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Goodwill	7,389	7,389
Indefinite-lived intangibles	119,820	'
Finite-lived intangibles	27,039	'
Intangible assets, net (excluding goodwill)	146,859	'
Intangible assets, net (including goodwill)	$154,248	'

Condensed_Consolidating_Financ2

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues	'	'	'	'
Net sales	$167,004	$161,323	$309,105	$307,243
Other revenues	1,438	532	2,308	1,609
Total revenues	168,442	161,855	311,413	308,852
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	73,723	71,310	133,211	134,703
Gross profit	94,719	90,545	178,202	174,149
Operating Expenses	'	'	'	'
Advertising and promotion	26,044	23,508	45,184	43,833
General and administrative	11,619	12,585	23,253	28,736
Depreciation and amortization	3,294	3,296	6,562	6,591
Total operating expenses	40,957	39,389	74,999	79,160
Operating income	53,762	51,156	103,203	94,989
Other (income) expense	'	'	'	'
Interest income	-25	-3	-28	-5
Interest expense	16,464	19,663	32,372	39,513
Equity in income of subsidiaries	0	0	0	0
Total other (income) expense	16,439	19,660	32,344	39,508
Income before income taxes	37,323	31,496	70,859	55,481
Provision (benefit) for income taxes	4,531	12,252	17,375	21,582
Net income	32,792	19,244	53,484	33,899
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	1,122	66	1,123	24
Total other comprehensive income	1,122	66	1,123	24
Comprehensive income	33,914	19,310	54,607	33,923
Prestige Brands Holdings, Inc.	'	'	'	'
Revenues	'	'	'	'
Net sales	0	0	0	0
Other revenues	0	0	0	0
Total revenues	0	0	0	0
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses	'	'	'	'
Advertising and promotion	0	0	0	0
General and administrative	891	895	2,390	2,724
Depreciation and amortization	517	137	1,034	269
Total operating expenses	1,408	1,032	3,424	2,993
Operating income	-1,408	-1,032	-3,424	-2,993
Other (income) expense	'	'	'	'
Interest income	-12,778	-12,242	-24,991	-24,370
Interest expense	8,687	8,746	17,294	17,412
Equity in income of subsidiaries	-30,922	-17,738	-50,777	-31,476
Total other (income) expense	-35,013	-21,234	-58,474	-38,434
Income before income taxes	33,605	20,202	55,050	35,441
Provision (benefit) for income taxes	813	958	1,566	1,542
Net income	32,792	19,244	53,484	33,899
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	1,122	66	1,123	24
Total other comprehensive income	1,122	66	1,123	24
Comprehensive income	33,914	19,310	54,607	33,923
Prestige Brands, Inc., the issuer	'	'	'	'
Revenues	'	'	'	'
Net sales	25,391	26,727	49,650	49,949
Other revenues	67	74	135	141
Total revenues	25,458	26,801	49,785	50,090
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	9,338	10,175	18,796	18,616
Gross profit	16,120	16,626	30,989	31,474
Operating Expenses	'	'	'	'
Advertising and promotion	3,748	2,777	7,188	5,884
General and administrative	1,481	1,707	3,124	3,436
Depreciation and amortization	143	139	285	280
Total operating expenses	5,372	4,623	10,597	9,600
Operating income	10,748	12,003	20,392	21,874
Other (income) expense	'	'	'	'
Interest income	-14,005	-11,061	-28,328	-22,021
Interest expense	16,464	28,410	32,372	56,926
Equity in income of subsidiaries	27,475	-20,995	12,922	-40,873
Total other (income) expense	29,934	-3,646	16,966	-5,968
Income before income taxes	-19,186	15,649	3,426	27,842
Provision (benefit) for income taxes	922	-2,080	4,009	-5,069
Net income	-20,108	17,729	-583	32,911
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	0	0	0	0
Total other comprehensive income	0	0	0	0
Comprehensive income	-20,108	17,729	-583	32,911
Combined Subsidiary Guarantors	'	'	'	'
Revenues	'	'	'	'
Net sales	134,164	133,277	250,783	254,934
Other revenues	1,431	524	2,294	1,586
Total revenues	135,595	133,801	253,077	256,520
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	61,513	61,175	111,502	116,210
Gross profit	74,082	72,626	141,575	140,310
Operating Expenses	'	'	'	'
Advertising and promotion	20,899	20,410	36,392	37,330
General and administrative	7,781	9,977	16,238	22,067
Depreciation and amortization	2,589	3,004	5,184	6,009
Total operating expenses	31,269	33,391	57,814	65,406
Operating income	42,813	39,235	83,761	74,904
Other (income) expense	'	'	'	'
Interest income	-710	0	-710	0
Interest expense	18,093	5,861	36,021	11,662
Equity in income of subsidiaries	-1,189	-780	-1,868	-913
Total other (income) expense	16,194	5,081	33,443	10,749
Income before income taxes	26,619	34,154	50,318	64,155
Provision (benefit) for income taxes	3,064	12,983	11,880	24,601
Net income	23,555	21,171	38,438	39,554
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	0	0	0	0
Total other comprehensive income	0	0	0	0
Comprehensive income	23,555	21,171	38,438	39,554
Combined Non-Guarantor Subsidiaries	'	'	'	'
Revenues	'	'	'	'
Net sales	7,449	1,319	8,672	2,360
Other revenues	668	519	1,102	994
Total revenues	8,117	1,838	9,774	3,354
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	3,600	545	4,136	989
Gross profit	4,517	1,293	5,638	2,365
Operating Expenses	'	'	'	'
Advertising and promotion	1,397	321	1,604	619
General and administrative	1,466	6	1,501	509
Depreciation and amortization	45	16	59	33
Total operating expenses	2,908	343	3,164	1,161
Operating income	1,609	950	2,474	1,204
Other (income) expense	'	'	'	'
Interest income	-22	-54	-24	-101
Interest expense	710	0	710	0
Equity in income of subsidiaries	0	0	0	0
Total other (income) expense	688	-54	686	-101
Income before income taxes	921	1,004	1,788	1,305
Provision (benefit) for income taxes	-268	391	-80	508
Net income	1,189	613	1,868	797
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	1,122	66	1,123	24
Total other comprehensive income	1,122	66	1,123	24
Comprehensive income	2,311	679	2,991	821
Eliminations	'	'	'	'
Revenues	'	'	'	'
Net sales	0	0	0	0
Other revenues	-728	-585	-1,223	-1,112
Total revenues	-728	-585	-1,223	-1,112
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	-728	-585	-1,223	-1,112
Gross profit	0	0	0	0
Operating Expenses	'	'	'	'
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total operating expenses	0	0	0	0
Operating income	0	0	0	0
Other (income) expense	'	'	'	'
Interest income	27,490	23,354	54,025	46,487
Interest expense	-27,490	-23,354	-54,025	-46,487
Equity in income of subsidiaries	4,636	39,513	39,723	73,262
Total other (income) expense	4,636	39,513	39,723	73,262
Income before income taxes	-4,636	-39,513	-39,723	-73,262
Provision (benefit) for income taxes	0	0	0	0
Net income	-4,636	-39,513	-39,723	-73,262
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	-1,122	-66	-1,123	-24
Total other comprehensive income	-1,122	-66	-1,123	-24
Comprehensive income	($5,758)	($39,579)	($40,846)	($73,286)

Condensed_Consolidating_Financ3

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Mar. 31, 2012
In Thousands, unless otherwise specified
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Ownership percentage	100.00%	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	$26,833	$15,670	$29,006	$19,015
Accounts receivable, net	80,534	73,053	'	'
Inventories	61,935	60,201	'	'
Deferred income tax assets	6,427	6,349	'	'
Prepaid expenses and other current assets	6,929	8,900	'	'
Total current assets	182,658	164,173	'	'
Property and equipment, net	11,256	9,896	'	'
Goodwill	191,058	167,546	'	'
Intangible assets, net	1,399,860	1,373,240	'	'
Other long-term assets	23,244	24,944	'	'
Intercompany receivable	0	0	'	'
Investment in subsidiary	0	0	'	'
Total Assets	1,808,076	1,739,799	'	'
Current liabilities	'	'	'	'
Accounts payable	51,857	51,376	'	'
Accrued interest payable	13,951	13,894	'	'
Other accrued liabilities	23,301	31,398	'	'
Total current liabilities	89,109	96,668	'	'
Long-term debt	'	'	'	'
Principal amount	985,000	978,000	'	'
Less unamortized discount	-6,302	-7,100	'	'
Long-term debt, net of unamortized discount	978,698	970,900	'	'
Deferred income tax liabilities	198,721	194,288	'	'
Long term liabilities	296	'	'	'
Intercompany payable	0	0	'	'
Total Liabilities	1,266,824	1,261,856	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	283	283	'	'
Common stock	520	513	'	'
Additional paid-in capital	410,664	401,691	'	'
Treasury stock, at cost - 191 shares	-965	-687	'	'
Accumulated other comprehensive income (loss), net of tax	1,019	-104	'	'
Retained earnings (accumulated deficit)	129,731	76,247	'	'
Total Stockholders' Equity	541,252	477,943	'	'
Total Liabilities and Stockholders' Equity	1,808,076	1,739,799	'	'
Prestige Brands Holdings, Inc.	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	23,668	14,720	27,722	18,221
Accounts receivable, net	133	21	'	'
Inventories	0	0	'	'
Deferred income tax assets	232	218	'	'
Prepaid expenses and other current assets	2,286	4,942	'	'
Total current assets	26,319	19,901	'	'
Property and equipment, net	10,791	9,609	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Other long-term assets	0	0	'	'
Intercompany receivable	654,016	653,049	'	'
Investment in subsidiary	1,538,436	1,429,775	'	'
Total Assets	2,229,562	2,112,334	'	'
Current liabilities	'	'	'	'
Accounts payable	2,084	2,601	'	'
Accrued interest payable	0	0	'	'
Other accrued liabilities	6,476	12,694	'	'
Total current liabilities	8,560	15,295	'	'
Long-term debt	'	'	'	'
Principal amount	0	0	'	'
Less unamortized discount	0	0	'	'
Long-term debt, net of unamortized discount	0	0	'	'
Deferred income tax liabilities	0	0	'	'
Long term liabilities	0	'	'	'
Intercompany payable	1,679,749	1,619,096	'	'
Total Liabilities	1,688,309	1,634,391	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	283	283	'	'
Common stock	520	513	'	'
Additional paid-in capital	410,664	401,691	'	'
Treasury stock, at cost - 191 shares	-965	-687	'	'
Accumulated other comprehensive income (loss), net of tax	1,019	-104	'	'
Retained earnings (accumulated deficit)	129,731	76,247	'	'
Total Stockholders' Equity	541,252	477,943	'	'
Total Liabilities and Stockholders' Equity	2,229,561	2,112,334	'	'
Prestige Brands, Inc., the issuer	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Ownership percentage	100.00%	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	12,879	13,875	'	'
Inventories	13,139	11,164	'	'
Deferred income tax assets	885	855	'	'
Prepaid expenses and other current assets	240	93	'	'
Total current assets	27,143	25,987	'	'
Property and equipment, net	20	34	'	'
Goodwill	66,007	66,007	'	'
Intangible assets, net	193,128	193,396	'	'
Other long-term assets	23,244	24,944	'	'
Intercompany receivable	1,918,831	1,911,573	'	'
Investment in subsidiary	682,450	638,611	'	'
Total Assets	2,910,823	2,860,552	'	'
Current liabilities	'	'	'	'
Accounts payable	9,304	10,600	'	'
Accrued interest payable	13,951	13,894	'	'
Other accrued liabilities	1,804	1,684	'	'
Total current liabilities	25,059	26,178	'	'
Long-term debt	'	'	'	'
Principal amount	985,000	978,000	'	'
Less unamortized discount	-6,302	-7,100	'	'
Long-term debt, net of unamortized discount	978,698	970,900	'	'
Deferred income tax liabilities	54,679	55,291	'	'
Long term liabilities	0	'	'	'
Intercompany payable	435,445	447,419	'	'
Total Liabilities	1,493,881	1,499,788	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	0	'	'
Common stock	0	0	'	'
Additional paid-in capital	1,337,706	1,280,945	'	'
Treasury stock, at cost - 191 shares	0	0	'	'
Accumulated other comprehensive income (loss), net of tax	0	0	'	'
Retained earnings (accumulated deficit)	79,236	79,819	'	'
Total Stockholders' Equity	1,416,942	1,360,764	'	'
Total Liabilities and Stockholders' Equity	2,910,823	2,860,552	'	'
Combined Subsidiary Guarantors	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Ownership percentage	100.00%	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	63,667	58,345	'	'
Inventories	45,401	48,474	'	'
Deferred income tax assets	5,310	5,276	'	'
Prepaid expenses and other current assets	4,396	3,609	'	'
Total current assets	118,774	115,704	'	'
Property and equipment, net	182	253	'	'
Goodwill	101,539	101,539	'	'
Intangible assets, net	1,174,410	1,179,524	'	'
Other long-term assets	0	0	'	'
Intercompany receivable	496,358	415,587	'	'
Investment in subsidiary	8,936	7,067	'	'
Total Assets	1,900,199	1,819,674	'	'
Current liabilities	'	'	'	'
Accounts payable	36,222	37,695	'	'
Accrued interest payable	0	0	'	'
Other accrued liabilities	13,096	16,107	'	'
Total current liabilities	49,318	53,802	'	'
Long-term debt	'	'	'	'
Principal amount	0	0	'	'
Less unamortized discount	0	0	'	'
Long-term debt, net of unamortized discount	0	0	'	'
Deferred income tax liabilities	143,970	138,924	'	'
Long term liabilities	0	'	'	'
Intercompany payable	928,333	920,865	'	'
Total Liabilities	1,121,621	1,113,591	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	0	'	'
Common stock	0	0	'	'
Additional paid-in capital	658,799	624,742	'	'
Treasury stock, at cost - 191 shares	0	0	'	'
Accumulated other comprehensive income (loss), net of tax	0	0	'	'
Retained earnings (accumulated deficit)	119,780	81,341	'	'
Total Stockholders' Equity	778,579	706,083	'	'
Total Liabilities and Stockholders' Equity	1,900,200	1,819,674	'	'
Combined Non-Guarantor Subsidiaries	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	3,165	950	1,284	794
Accounts receivable, net	3,855	812	'	'
Inventories	3,395	563	'	'
Deferred income tax assets	0	0	'	'
Prepaid expenses and other current assets	411	256	'	'
Total current assets	10,826	2,581	'	'
Property and equipment, net	263	0	'	'
Goodwill	23,512	0	'	'
Intangible assets, net	32,322	320	'	'
Other long-term assets	0	0	'	'
Intercompany receivable	9,102	7,316	'	'
Investment in subsidiary	0	0	'	'
Total Assets	76,025	10,217	'	'
Current liabilities	'	'	'	'
Accounts payable	4,247	480	'	'
Accrued interest payable	0	0	'	'
Other accrued liabilities	2,329	913	'	'
Total current liabilities	6,576	1,393	'	'
Long-term debt	'	'	'	'
Principal amount	0	0	'	'
Less unamortized discount	0	0	'	'
Long-term debt, net of unamortized discount	0	0	'	'
Deferred income tax liabilities	72	73	'	'
Long term liabilities	296	'	'	'
Intercompany payable	34,780	145	'	'
Total Liabilities	41,724	1,611	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	0	'	'
Common stock	0	0	'	'
Additional paid-in capital	23,815	1,111	'	'
Treasury stock, at cost - 191 shares	0	0	'	'
Accumulated other comprehensive income (loss), net of tax	1,019	-104	'	'
Retained earnings (accumulated deficit)	9,467	7,599	'	'
Total Stockholders' Equity	34,301	8,606	'	'
Total Liabilities and Stockholders' Equity	76,025	10,217	'	'
Eliminations	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0	'	'
Inventories	0	0	'	'
Deferred income tax assets	0	0	'	'
Prepaid expenses and other current assets	-404	0	'	'
Total current assets	-404	0	'	'
Property and equipment, net	0	0	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Other long-term assets	0	0	'	'
Intercompany receivable	-3,078,307	-2,987,525	'	'
Investment in subsidiary	-2,229,822	-2,075,453	'	'
Total Assets	-5,308,533	-5,062,978	'	'
Current liabilities	'	'	'	'
Accounts payable	0	0	'	'
Accrued interest payable	0	0	'	'
Other accrued liabilities	-404	0	'	'
Total current liabilities	-404	0	'	'
Long-term debt	'	'	'	'
Principal amount	0	0	'	'
Less unamortized discount	0	0	'	'
Long-term debt, net of unamortized discount	0	0	'	'
Deferred income tax liabilities	0	0	'	'
Long term liabilities	0	'	'	'
Intercompany payable	-3,078,307	-2,987,525	'	'
Total Liabilities	-3,078,711	-2,987,525	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	0	'	'
Common stock	0	0	'	'
Additional paid-in capital	-2,020,320	-1,906,798	'	'
Treasury stock, at cost - 191 shares	0	0	'	'
Accumulated other comprehensive income (loss), net of tax	-1,019	104	'	'
Retained earnings (accumulated deficit)	-208,483	-168,759	'	'
Total Stockholders' Equity	-2,229,822	-2,075,453	'	'
Total Liabilities and Stockholders' Equity	($5,308,533)	($5,062,978)	'	'

Condensed_Consolidating_Financ4

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating Activities	'	'
Net income (loss)	$53,484	$33,899
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	6,562	6,591
Deferred income taxes	4,355	12,391
Amortization of deferred financing costs	1,975	2,060
Stock-based compensation costs	2,487	1,973
Amortization of debt discount	798	812
Gain on sale of assets	-3	51
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-5,712	-24,530
Inventories	821	-2,904
Prepaid expenses and other current assets	2,619	5,556
Accounts payable	-1,125	15,150
Accrued liabilities	-10,663	8,350
Net cash provided by operating activities	55,598	60,374
Investing Activities	'	'
Purchases of property and equipment	-2,319	-5,266
Proceeds from the sale of property and equipment	3	15
Acquisition of Care Pharmaceuticals, less cash acquired	-55,215	0
Acquisition of GSK purchase price adjustments	0	-226
Intercompany activity, net	0	0
Net cash used in investing activities	-57,531	-5,477
Financing Activities	'	'
Repayments of long-term debt	-7,500	-70,000
Repayments under revolving credit agreement	-35,500	-8,000
Borrowings under revolving credit agreement	50,000	33,000
Payment of deferred financing costs	-275	0
Proceeds from exercise of stock options	5,143	80
Excess tax benefits from share-based awards	1,350	0
Shares surrendered as payment of tax withholding	-278	0
Intercompany activity, net	0	0
Net cash provided by (used in) financing activities	12,940	-44,920
Effects of exchange rate changes on cash and cash equivalents	156	14
Increase in cash and cash equivalents	11,163	9,991
Cash and cash equivalents - beginning of period	15,670	19,015
Cash and cash equivalents - end of period	26,833	29,006
Prestige Brands Holdings, Inc.	'	'
Operating Activities	'	'
Net income (loss)	53,484	33,899
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	1,034	269
Deferred income taxes	-14	109
Amortization of deferred financing costs	0	0
Stock-based compensation costs	2,487	1,973
Amortization of debt discount	0	0
Gain on sale of assets	0	30
Equity in income of subsidiaries	-50,777	-31,476
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-112	-117
Inventories	0	0
Prepaid expenses and other current assets	2,656	6,259
Accounts payable	-517	-2,394
Accrued liabilities	-6,218	-2,516
Net cash provided by operating activities	2,023	7,011
Investing Activities	'	'
Purchases of property and equipment	-2,216	-5,266
Proceeds from the sale of property and equipment	0	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	'
Acquisition of GSK purchase price adjustments	'	0
Intercompany activity, net	'	-226
Net cash used in investing activities	-2,216	-5,492
Financing Activities	'	'
Repayments of long-term debt	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	'
Proceeds from exercise of stock options	5,143	80
Excess tax benefits from share-based awards	1,350	'
Shares surrendered as payment of tax withholding	-278	'
Intercompany activity, net	2,926	7,902
Net cash provided by (used in) financing activities	9,141	7,982
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase in cash and cash equivalents	8,948	9,501
Cash and cash equivalents - beginning of period	14,720	18,221
Cash and cash equivalents - end of period	23,668	27,722
Prestige Brands, Inc., the issuer	'	'
Operating Activities	'	'
Net income (loss)	-583	32,911
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	285	280
Deferred income taxes	-642	1,676
Amortization of deferred financing costs	1,975	2,060
Stock-based compensation costs	0	0
Amortization of debt discount	798	812
Gain on sale of assets	0	0
Equity in income of subsidiaries	12,922	-40,873
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	996	-1,935
Inventories	-1,975	205
Prepaid expenses and other current assets	-147	-48
Accounts payable	-1,296	2,759
Accrued liabilities	177	424
Net cash provided by operating activities	12,510	-1,729
Investing Activities	'	'
Purchases of property and equipment	0	0
Proceeds from the sale of property and equipment	0	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	'
Acquisition of GSK purchase price adjustments	'	0
Intercompany activity, net	'	0
Net cash used in investing activities	-55,215	0
Financing Activities	'	'
Repayments of long-term debt	-7,500	-70,000
Repayments under revolving credit agreement	-35,500	-8,000
Borrowings under revolving credit agreement	50,000	33,000
Payment of deferred financing costs	-275	'
Proceeds from exercise of stock options	0	0
Excess tax benefits from share-based awards	0	'
Shares surrendered as payment of tax withholding	0	'
Intercompany activity, net	35,980	46,729
Net cash provided by (used in) financing activities	42,705	1,729
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Subsidiary Guarantors	'	'
Operating Activities	'	'
Net income (loss)	38,438	39,554
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	5,184	6,009
Deferred income taxes	5,012	10,612
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Amortization of debt discount	0	0
Gain on sale of assets	-3	21
Equity in income of subsidiaries	-1,868	-913
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-5,322	-21,910
Inventories	3,073	-3,319
Prepaid expenses and other current assets	-787	-980
Accounts payable	-1,473	14,109
Accrued liabilities	-3,011	10,229
Net cash provided by operating activities	39,243	53,412
Investing Activities	'	'
Purchases of property and equipment	0	0
Proceeds from the sale of property and equipment	3	15
Acquisition of Care Pharmaceuticals, less cash acquired	0	'
Acquisition of GSK purchase price adjustments	'	-226
Intercompany activity, net	'	226
Net cash used in investing activities	3	15
Financing Activities	'	'
Repayments of long-term debt	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	'
Proceeds from exercise of stock options	0	0
Excess tax benefits from share-based awards	0	'
Shares surrendered as payment of tax withholding	0	'
Intercompany activity, net	-39,246	-53,427
Net cash provided by (used in) financing activities	-39,246	-53,427
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Non-Guarantor Subsidiaries	'	'
Operating Activities	'	'
Net income (loss)	1,868	797
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	59	33
Deferred income taxes	-1	-6
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Amortization of debt discount	0	0
Gain on sale of assets	0	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-1,274	-568
Inventories	-277	210
Prepaid expenses and other current assets	493	325
Accounts payable	2,161	676
Accrued liabilities	-1,207	213
Net cash provided by operating activities	1,822	1,680
Investing Activities	'	'
Purchases of property and equipment	-103	0
Proceeds from the sale of property and equipment	0	0
Acquisition of Care Pharmaceuticals, less cash acquired	-55,215	'
Acquisition of GSK purchase price adjustments	'	0
Intercompany activity, net	'	0
Net cash used in investing activities	-103	0
Financing Activities	'	'
Repayments of long-term debt	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	'
Proceeds from exercise of stock options	0	0
Excess tax benefits from share-based awards	0	'
Shares surrendered as payment of tax withholding	0	'
Intercompany activity, net	340	-1,204
Net cash provided by (used in) financing activities	340	-1,204
Effects of exchange rate changes on cash and cash equivalents	156	14
Increase in cash and cash equivalents	2,215	490
Cash and cash equivalents - beginning of period	950	794
Cash and cash equivalents - end of period	3,165	1,284
Eliminations	'	'
Operating Activities	'	'
Net income (loss)	-39,723	-73,262
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	0	0
Deferred income taxes	0	0
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Amortization of debt discount	0	0
Gain on sale of assets	0	0
Equity in income of subsidiaries	39,723	73,262
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	0	0
Inventories	0	0
Prepaid expenses and other current assets	404	0
Accounts payable	0	0
Accrued liabilities	-404	0
Net cash provided by operating activities	0	0
Investing Activities	'	'
Purchases of property and equipment	0	0
Proceeds from the sale of property and equipment	0	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	'
Acquisition of GSK purchase price adjustments	'	0
Intercompany activity, net	'	0
Net cash used in investing activities	0	0
Financing Activities	'	'
Repayments of long-term debt	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	'
Proceeds from exercise of stock options	0	0
Excess tax benefits from share-based awards	0	'
Shares surrendered as payment of tax withholding	0	'
Intercompany activity, net	0	0
Net cash provided by (used in) financing activities	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	$0	$0